­º­¶ ] ¦V¤W ] ­ìµÛ§Ç¨¥ ] ºK­n ] ²Ä¤@³¹¡@¤j¨Æ°O ] ²Ä¤G³¹¡@¯f¬r¾Ç ] ²Ä¤T³¹ ¶Ç¼½ ] ²Ä¥|±i¡@¬y¦æ¯f¾Ç ] [ ²Ä¤­³¹¡@¹w¨¾ ] ²Ä¤»³¹¡@SARS¯f¨Ò©w¸q ] ¶EÂ_¸ÕÅç ] ²Ä¤K³¹  Á{§Éªí²{©M¶EÂ_ ] ²Ä¤E³¹¡@ªvÀø ] ²Ä¤Q³¹¡@¤p¨àSARS ]

 

²Ä¤­³¹¡@¹w¨¾

Bernd Sebastian Kamps, Christian Hoffmann

 

§Ç½×

 

SARS©M¬y¦æ©Ê·P«_©Î¼w°ê³Â¯lµ¥¯e¯f¤ñ°_¨Ó¥u·|¾A«×¦a¶Ç¬V¡C§Ú­Ì±q¬y¦æ¯f¾Çªº¬ã¨s¤¤µo²{¡GSARSªº¨C­Ó±a­ìªÌ¥­§¡¶Ç¬Vµ¹2.2¨ì3.6­Ó®×¨Ò¡A³oºØ·P¬Vªº¾÷²v¤ñ¨ä¥L¸g¥Ñ©I§l¹D·P¬Vªº¯e¯f¾÷²vÁÙ¤p(Lipsitch)¡C³oªí¥Ü»¡ºÞ²z±¹¬Iªºµ²¦X¹B¥Î¥]¬AÁYµu±q±wªÌµo¯f¨ì³Q¹jÂ÷ªº®É¶¡¡B¦³®Ä¦a±N±µÄ²¹L±wªÌ©Î¨ì¹L¬Ì°Ïªº¤H§@Àˬ̹jÂ÷µ¥³£¬O¥i¯à¨¾¤îSARS³QÂX´²ªº¦³®Ä¤èªk¡Cªº½T¡A³o¼Ë¤èªk¬O¦¨¥\ªº¦Ó¥BÀ³¥Î¦b¨ä¥L°ê®a¯à¦³®Ä¦a¨¾¤îSARS¼ÉµoÄY­«ªº¬Ì±¡¡C¥t¤@¤è­±¡A¤@¥¹¨S¦³³oºØ¦³®Ä¤èªk®É¡ASARS´N¦³¥i¯à³Q¼sªx¶Ç¼½(Lipsitch)¡C

 

¦b¥Ø«e¨S¦³¦³®Äªº¬Ì­]¥X²{®É¡A­n±±¨î³oºØ­P©R©Ê¯e¯f¦pSARSªº¦³®Ä¤èªk¬O¡A¯}Ãa±¼¨ä¤¤ªº¶Ç¬V³~®|¡C¦b©Ò¦³®×¨Ò¤¤¡ASARSªº¶Ç¼½¥D­n¤è¦¡¬Oªñ¶ZÂ÷ªº­±¹ï­±±µÄ²¤¤¡A³Q±wªÌ¥´¼QÀ¡©Î«y¹Â©Ò²£¥Íªº­¸ªj¶Ç¬V(WHO / WER 20/2003)¡C

 

¹ï¥ISARS¦³¤T¼h­± ¢w §Y¬O°»´ú¥i¯àªº®×¨Ò¡B±N±wªÌ¹jÂ÷©M°lÂÜ´¿©M±wªÌ±µÄ²¹Lªº¤H¡A³o¼Ë¥i¥H´î¤Ö¨º¨Ç°ª¦MÀI¸sµo¯fªº¾÷·|¡A³Ì«á¥i¥H¯}Ãa¶Ç¼½³~®|(WHO / WER 20/2003)¡G

1. °»´ú®×¨Òªº¥Øªº¬O¡AºÉ¥i¯à¦bµo¯f«á§Ö³t¦a¿ëÃÑ¥X¬O§_¬°SARS¡C

2. ¤@¥¹³Q½T»{«á¡A¤U¤@¨B¬O­n®Ú¾Ú¡uÄY­«¶Ç¬V©Ê¯e¯f±±¨î±ø¨Ò¡v¡A¥Î§´µ½¦a³]³Æ±N±wªÌ¥ß§Y¹jÂ÷¡C

3. ²Ä¤T­Ó¼h­± ¢w ½Õ¬d¤u§@ ¢w¥]§t©Ò¦³´¿©M¯f¤H±µÄ²¹Lªº¤H¡A¨Ã½T»{¥L­Ìªº°·±d±¡§Î¡A¦p¥L­Ì¨C¤@¤Ñªº°·±dÀˬd¬O§_¥¿±`¡B¬O§_¦³½T¹ê§@¨ì©~®a¹jÂ÷¡C

³o¤T­Ó¼h­±¥i±±¨î°ª¦MÀI¸s©¼¦¹±µÄ²ªº¾÷·|¡A¨Ã¥B¥i¥HÁYµuµo¯f¨ì±wªÌ³Q¹jÂ÷©Ò®ö¶Oªº®É¶¡¡A¦]¦¹¥i­°§C¯f¬r¶Ç¼½¨ì¨ä¥L±wªÌªº¾÷²v(WHO / WER 20/2003)¡C

 

 

°ê»Ú¦X§@

 

¥@¬É½Ã¥Í²Õ´(WHO)¦b³ò°ô¥þ²y²Ä¤@°_ªºSARS®×¨Ò¤¤¦ñºt¤@­ÓÃöÁ䨤¦â¡C

 

¥Ñ©ó¶V«nªe¤º¤Î­»´äªºÂå°|­û¤u¡A¦b3¤ë12¤é·P¬V¤FºÃ¦ü«D¨å«¬ªÍª¢®×¥ó«á¦Óµo¥X¤F¥þ²yªºÄµ°T¡A¤§«áWHO¤S³°Äò±µ¨ì§ó¦h®×¥ó¡C¤T¤Ñ¥H«á¡AWHO¹ï¬ÛÃöªºÂåÀø³æ¦ì¡BÂå®v©M·Q­n¥X¥~®È¦æªº¥Á²³µo¥Xºò«æ®È¦æ³q§i¡Aĵ§i¤j®a³o¬O¤@ºØ«Â¯Ù¥@¤H°·±dªº¯e¯f¡C¹ï¨º¨Ç­n¥X°ê®È¹Cªº¥Á²³¤Î¬ÛÃö³æ¦ìªºÂåÀø¤H­û´£¥Xĵ§i¡A±q¬Ì°Ï¦^¨Ó«áªº10¤Ñ¬Oµo¯fªºÃöÁä´Á¡C(http://www.who.int/csr/sarsarchive/2003_03_15/en/)  

 

³o¶µ¨M©w¬O®Ú¾Ú¤­­Ó¤£¦P¡A¦ý©¼¦¹¬ÛÃö­ì¦](WHO¡AStatus of the Outbreak)¡G

1. ³o­Ó¯e¯f¤Þ°_ªº­ì¦]©|¤£²M·¡¡A¦Ó¥BÁÙ·|¤£Â_¶Ç¼½¥X¥h¡C

2. ³o­Ó¯e¯f·|¨Ï¨º¨Ç©M¯f±w±µÄ²¹LªºÂåÀø¬ÛÃö¤H­û©M¯f±wªº®aÄÝ¡A¤Î´¿¸g©M±wªÌ±µÄ²¹Lªº¤H¡A¦¨¬°¶Ç¼½ªº°ª¦MÀI¸s¡C

3. ³\¦h¤£¦Pªº§Ü¥Í¯À©M§Ü¯f¬rÀøªk³£³Q¸Õ¹L¡A¦ý¦ü¥G¨S¦³§@¥Î¡C

4. ÁöµM·P¬Vªº¤H¼Æ­è¶}©l«Ü¤Ö¡A¦ý¦h¼Æ±wªÌ(ªe¤ºÂå°|26¤H¤¤¦³25¤H©M­»´äÂå°|39¤H¤¤¦³24¤H)«Ü§Ö¦a·|©I§l§xÃø¡A¨Ã»Ý­n±µ¨ü§ó¶i¤@¨BªºªvÀø¡A¦Ó³Ì«á¾É­P³o¨Ç­ì¥»°·±dªº¤H³¡¤À¦º¤`®×¨Ò¡C

5. ³oºØ¯e¯f¤w¥Ñ³Ìªìªº¨È¬w¦Ó¶}©l¶Ç¼½¨ì¥_¬ü¬w©M¼Ú¬w¡C

 

¦b¤£¨ì¤G­Ó¬P´Áªº®É¶¡¡AWHO©Ò¦¨¥ßªº¬ã¨s¹Î¶¤´Nµo²{SARS¬O¥Ñ¤@ºØ¡u«aª¬

¯f¬r¡qcoronavirus¡r¡v©Ò¤Þ°_(°Ñ¨£²Ä¤G³¹¡G¯f¬r¾Ç)¡C

 

¥|¤ëªì¡AWHOµo§G¤F¤@¶µ«Ü¯S®íªº®È¹C«ØÄ³¡A4¤ë2¤é¡AWHO±N­»´ä©M¤¤°êªº

¼sªF¬Ù¦C¤J®È¹C¬Ì°Ï

(http://www.who.int/csr/sarsarchive/2003_04_02/en /)

 

 4¤ë23¤é¡AWHO±N¤¤°êªº¥_¨Ê©MÔE¦è¬Ù¤Î¥[®³¤jªº¦h­Û¦h

(http://www.who.int/csr/sarsarchive/2003_04_23/en /) ¥H¤Î5¤ë8¤é±N¤Ñ¬z¡B¤º»X

¥j©M¥xÆWªº¥x¥_¤]¦C¤J®È¹C¬Ì°Ï¤¤ (WHO Update 50)¡C

 

¦bWHO¤£Â_¦aµo¥¬Äµ°T©M¥þ¥@¬É¤H­Ìªº§V¤O¦X§@¤U¡A²×©ó¹F¨ì³ò°ô¬Ì±¡ªº¥Ø

¼Ð¡A©Ò¦³ªº°ê®a¹ï©ó°£¤F¤¤°ê¥H¥~¨º¨Ç­n¤J¹Òªº®È«È¡A³£¯à¥ß¨è§@¨ì¥H¤Uªº´XÂI¡G

1. °»´ú¬O§_·P¬V

2. ­Y¬°ºÃ¦ü¯f¨Ò¡A¥ß¨è¹jÂ÷¨Ã¶i¦æÄY±Kªº¶Ç¬V±±¨î

3. °lÂܯf¨Ò¨Ó·½¡A¦p·P¬V·½¡B¯f¨Òªº¬¡°Ê°O¿ý¡B´¿©M¯f¨Ò±µÄ²¹Lªº¤Hµ¥

¦p¦¹«K¥i¥H¨¾¤î§ó¶i¤@¨Bªº¶Ç¼½©ÎÁ×§K·P¬Vªº¤H¼Æ¼W¥[¡A§Ú­Ì¥i¥H±N³o®M¦³®Äªº¤èªk°µ¬°¤é«á¹ï§Ü¨ä¥L¬y¦æ¯fªº¨å½d¡C

¦b¤C¤ëªì¡A©Ò¦³®È¦æ´ºÂI³£±qWHOªº¬Ì°Ï¦W³æ¤¤°£¦W¤F (WHO Update 96)

 

 

¹ï®È¹CªÌªº«ØÄ³

 

¹ï¨º¨Ç­n¥X°ê®È¹Cªº¹C«È­n´£¿ô´XÂISARSªº¯gª¬¡G

1. µo¿N¯gª¬ (Åé·Å¶W¹LÄá¤ó38«×©ÎµØ¤ó100.4«×)

2. °®«y

3. ©I§l«æ«P©Î©I§l§xÃø

 

­Yµo²{¦³¥H¤W¯gª¬¦Ó¥B­è±q¬Ì°Ï¦^¨Óªº¥Á²³­n¥ß¨è´NÂå (WHO WER 14/2003)

?¤F­°§C®È«È·|±NSARS¯f¬r±a¨ì·sªº¦a°Ï¡A¨º¨Ç¦bB¯Å©ÎC¯Å¬Ì°Ï(°Ñ¦Ò"WHO¤½§Gªº¬Ì°Ï¦W³æ", http://www.who.int/csr/sarsareas/en/ ) ªº®È«È·|¦AÂ÷¹Ò®É³Q­n¨D§@ÀË´ú¡A¥]¬A³Q°Ý¤G­Ó©Î¤T­Ó°ÝÃD©M¶qÅé·Å¡A¤@¥¹®È«È¥X²{ºÃ¦üSARS¯gª¬¦pµo¿N©Î·P«_¡A©Î¦³¨ì¹L¬Ì°Ïªº°O¿ý¡A³£·|³QÂåÀø¤H­û­n¨D¹jÂ÷Æ[¹î¡Aª½¨ì§¹¥þ±d´_¬°¤î¡C°Ñ¦Ò International Cruise Vessels©Ò«ØÄ³ªºSARS¹w¨¾¤èªk(ªþµù¤@)¡C   http://www.who.int/csr/sars/travel/vessels/en/

 

 

°ê¤º±¹¬I

 

¹ï©ó¨S¦³©Î¥u¦³¹s¬P¯f¨Ò¶Ç¥Xªº°ê®a¦Ó¨¥¡AºÊ±±SARSªº­«ÂI¦b©ó¹ïºÃ¦ü·P¬VSARSªº¯f±w¡A¦­´ÁªºÅ²§O¨Ã¥[¥H¹jÂ÷¡C

 

¬Û¤Ïªº¡A¦b¨º¨Ç¤w¸g¦³ÄY­«¬Ì±¡Ãzµoªº°ê®a¡A´N¥²¶·¹ê¬I¤£¦P¥B¦³®É­Ô¨Ã¤£¨üÅwªïªº±¹¬I¡A¨Ó¹K¤îSARSªº¶Ç¼½¡A³o¨Ç±¹¬I³q±`¥]§t¥H¤U´X¶µ¡G

1.                                                          ³]¥ßºò«æ¨¾ªv¤¤¤ß¡C

2.                                                          ³]¥ß¤@¨ì¦h®aªºSARS±MªùÂå°|¡C

3.                                                          °ò©ó¼s¸qªº¯f¨Ò©w¸q¡A­q¥ß¦³®Ä²vªº¹jÂ÷±¹¬I¡C¡]¨£¥H¤U±Ô­z¡^

4.                                                          ¨³³tªº­q©w¬ÛÃöªk³W¡C

 

¦b·s¥[©Y¡A·í¬Ì±¡¨Ì¶}©l¦ÛTan Tock SengÂå°|Ãzµo®É¡A³o¶¡¥þ°ê²Ä¤G¤jªºÂå°|¡]¾Ö¦³1500­Ó§É¦ì¡^³QÃö³¬¨Ã¥B·í§@SARSªº±MªùÂå°|¡C¾Ç®Õ¥þ³¡°±¤î¤W½Ò¡A¦Ó°ê¤º©Ò¦³ªº¤½¶}¬¡°Ê¡A°¨¤W³Q«Å¥¬©µ«á¡C·s¥[©Y¬F©²¨Ã§Q¥Î­x¤èªº¤O¶q¡A¨Ó¨ó§U°lÂܨñj¨î©~®a¹jÂ÷ªº¹ê¦æ¡C´¿¸g©ó¯fµo¤§«e¤Q¤Ñ¦b¤£½×©~®a¤è­±¡B¤u§@¤è­±©Î¦bÂå°|±µÄ²¹Lªº¤H¡A³£­n¤©¥H°lÂÜ¥HŲ©w¥X¶Ç¬Vªº¨Ó·½¡C¦Ó¨º¨Ç³Q»{©w¬°±q¯f¯gµo§@¡A¨ì³Q¹jÂ÷³o¬q´Á¶¡¤º´¿±µÄ²¯f¤Hªº¤H¡A³Q­n¨D¶i¦æ©~®a¹jÂ÷¡C¨ä¥Lªº±¹¬I¥]¬A¤F¦³ºÊ±±¾÷³õ¤Î´ä¤fªº¨Ó©¹®È«È¡B¦b¨C¶¡Âå°|ÄY®æ°õ¦æÁµ´³X«È±´µøªº³W©w¡A¨Ã¥B§Q¥Î¦ÛÄ@®½Ämªº±ÏÅ@¨®¡A¹B°e©Ò¦³¥i¯à¯f¨Ò¨ìSARS±MªùÂå°|¡C­x¤è¤O¶q³Q³¡¸p©ó«ùÄòªº°lÂÜ¡A¨Ã±j¨î°õ¦æ¹jÂ÷ªº±¹¬I¡A¥ô¦óªºÂå°|¬Ò¤£¤¹³\¦³³X«È±´µø¯f¤H¡C

 

¦b¥xÆW¡A½Ã¥Í¸pÂǥѩó¥þ®q¦U¦a³]¥ßSARS±MªùÂå°|¡A¨Ó­­¨î°|¤º·P¬Vªºµ{«×¡C¦P®É¤]¦b¦U­ÓÂå°|³]¥ß¤F¬ù100­Óµo¿NÀË´ú¯¸¨Ó´À¥i¯à¬OSARS·P¬V¯f¨Òªº¥Á²³°µ¿zÀË¡A¦P®É¤]­°§C¤F¦bÂå°|«æ¶E«Ç¶Ç¼½¯f¬rªº¥i¯à©Ê¡C¨Ã¥B¦b¥þ°ê¦w±Æ¤FÃB¥~1000­Ó­tÀ£¹jÂ÷¯f©Ð¥H§@¬°¯f±wªº¬ÝÅ@¤§¥Î¡C¦ÓÀç¦a¥H¤Î­x¤è³]¬I¤]³Q¥Î§@¦w¸m¹jÂ÷ªÌ¤§¥Î¡A¦Ó©~®a¹jÂ÷¤]§Q¥Îºô¸ôÄá¼v¾÷ªº³]¸m¨Ó±j¨î°õ¦æ¡C

 

 

¨î©wªk³W

 

·s¥[©Y¬F©²©ó¥|¤ë¤G¤Q¥|¤é¹ï©ó¶Ç¬V¯e¯fªk°µ¤F­×¥¿¡A¨Ï±o¹Hªkªº¥Á²³¥²¶·±µ¨ü¦D»@¡A¦Ó¦¹ªk­n¨D¥i¯à±a¦³¶Ç¬V¯fªº¥Á²³¡A¥²¶·¨ì«ü©wªºªvÀø¤¤¤ß±µ¨üªvÀø¡A¨Ã¸T¤î¥L­Ì¨ì¤½¦@³õ¦X¥X¤J¡A¥t¥~¡A¤]¸T¤î¹H¤Ï©~®a¹jÂ÷¡A¹H¤ÏªÌ¥i¯à·|³Q©ë¯d¡A¦P®É¤]­ã³\³Q¦Ã¬Vªº°Ï°ì¡A¥i°µ¹jÂ÷ªº±¹¬I¡A¨Ã±N¥iºÃªº·P¬V·½¤©¥HºR·´¡C°£¦¹¤§¥~¡A¥þ°êªº¥Á²³³£³Q­n¨D´ú¶qÅé·Å¡A¤@¥¹¦³¥ô¦óºÃ¦üSARSªº¯gª¬²£¥Í®É¡A«K­n«Ý¦b®a¤¤©Î´M¨DÂåÀø¬ÝÅ@¡C³o¶µ¥ßªk¤¹¤]³\·s¥[©Y¦w¥þ§½¡A0ÂǥѦb©~®a¹jÂ÷ªº¥Á²³®a¤¤³]¸mePIC¡]electric picture¡^camera¡A±j¨î°õ¦æ¬°´Á10¤Ñªº©~®a¹jÂ÷

¦Ó¹H¤Ï¦¹¤@¹jÂ÷ªº¥Á²³¡A±N·|³Q³B¥H³Ì¦h5800¬üª÷ªº»@´Ú¤Î¤»­Ó¤ëªº¦D´Á¡C

 

¼s¸qªº¯f¨Ò©w¸q

 

¹w¨¾ªº¥Ø¼Ð¦b©óŲ§O¡A¨Ã¹jÂ÷©Ò¦³ºÃ¦ü¾DSARS¯f¬r·P¬Vªº¥Á²³¡C¥Ø«e¥ÑWHOµo¥¬ªº¯f¨Ò©w¸qªº¥D­n¶EÂ_¨Ì¾Ú¦³¡G°ª¿N¡]¶W¹LÄá¤ó38«×¡^¡B«y¹Â¡B©I§l«æ«P©Î©I§l§xÃøµ¥ªº©I§l¹D¯gª¬¡A¥H¤Î¦³´¿¸g¼ÉÅS¦b¯f·½ªº¸gÅç¡]¸Ô²Ó»¡©ú½Ð¨£¡¨¯f¨Ò©w¸q¡¨³¹¸`¡^¡C³o¼Ëªº©w¸q¥i¯à¤£¨¬¥HÀ³¥IÃzµoªº¬Ì±¡¡C

 

¦b¤@¶µ¬ã¨s·í¤¤«ü¥X¡A¦­´ÁªºSARSÃѧO¯gª¬¨Ã¤£¬O«y¹Â©Î©I§l§xÃø¡A¦Ó¬Oµo¿N¡B´HŸ¡Bµê®z¤£¾A¡B¦Ù¦×µmµh¡B¦Ù¦×±jª½¡A¨Ã¥i¯à·|¦³¸¡µh©ÎÀYµhªº±¡§Îµo¥Í¡Cµo¿N¦b¦­´Á¯gª¬¤¤¨Ã¤£±`¨£¡A¦Ó¼v¹³¶EÂ_¾Ç¤]¦³ÃÒ¾ÚÅã¥Ü¡AªÍ³¡ªºÅܤƳq±`¬O¤Þ°_µo¿Nªº­ì¦]¡C³o¶µ¬ã¨sªº§@ªÌ­pºâ¥X¨Ì¾ÚWHOªº©w¸q¡A¦³26¢Mªº±Ó·P«×¡A¦Ó«o¦³85¢M¹w´ú¥¢±Ñ¾÷²v¡C³o¼Ëªº¯f¨Ò©w¸q¡A¥D­n¬O°ò©ó¯f±w¤w¸g¶i¨ìÂå°|±µ¨üªvÀø¡A¦]¦¹¥i¯à¥u©w¸q¥X¤F¦B¤s¤@¨¤ªº¯f¨Ò¡A¦]¦¹³o¼Ëªº©w¸q¹ï©óÁÙ¥¼´NÂ媺¥Á²³¨Ó»¡¬O¤£°÷±Ó·Pªº¡C

 

¥t¥~¡A³q±`¨º¨Ç¦³©úÅã¥~¦b¯gª¬ªí²{ªº¯f¤H¡A¨Ã¤£¬O³y¦¨¬Ì±¡ÂX¤jªº¥D­n­ì¦]¡A¤Ï¦Ó¬O¨º¨Ç¥¼³Q¤Î®É¶E¹î¥X¨ÓªºÁô©Ê¯f¨Ò¡A¬O¥Ø«e¬°¤î³y¦¨¬Ì±¡§ó¥[´c¤Æªº·½ÀY¡C¥H¤U´X­Ó¦]¯À·|³y¦¨Å²§OSARS¯f¨ÒªºÃø«×¼W¥[¡G

l          ¦­´Áªº¯gª¬³q±`¬O«D¯S©w©Êªº¡A¦]¦¹®e©ö»P¨ä¥L´¶³qªº¯f¯g³y¦¨²V²c¡C¦p«æ©Ê¸z­Gª¢¡B«æ©ÊµÇª»µÇª¢¡B¤@¯ë¬y¦æ·P«_µ¥¡C

l          ¦b¦³§K¬Ì¾÷¯à¯Ê¥F©Î¬OºC©Ê¯f¡]¦p¿}§¿¯f©Î¬OºC©ÊµÇ°IºÜ¡^ªº¯f¤H¨­¤W¡A¦b¬V¯fªº«æ©Ê´Á¡A¦³¥i¯à¨Ã¤£·|¥X²{µo¿N©Î¤W­z¨ä¥L©úÅ㪺¯gª¬¡A¦p¦¹·|¨Ï±oSARSªº¶EÂ_¨ü¨ì©µ»~¡C

l          ¬Y¨Ç¯f±w¥i¯à·|¦³¤£ªÖ³zº|¬Y¨Ç¦³®Ä¸ê°T¡]¨Ò¦p´¿±µÄ²¹L»PSARS¯f±w©Î¦³²o³sªºÂåÀø¬ÝÅ@¡^ªº¥i¯à¡A¨ä­ì¦]¥i¯à¬O¦]¬°®`©È¾D¨ìªÀ·|¥Î²§¼Ë²´¥ú¬Ý«Ý¡A©Î¬O³y¦¨ªB¤Í©Î®a¤H¤]³s±a³Q¹jÂ÷ªºÀ£¤O¡C

 

¥H¤W´X­Ó¦]¯À©Ò¥]§tªº®×¨Ò³q±`¯Ê¥Fĵı¤ß¡A¦]¦¹¨S¦³³Q¹jÂ÷©Î¬O¨Ì·ÓÄY®æªºµ{§Ç³Q¦w¸m¥H¨¾¤î¶Ç¬V¡A¦]¦¹¦b¨S¦³­­¨î³X«Èªº±¡ªp¤U¡A¦A±µ¨ü¶i¤@¨BªºÀˬd©ÎªvÀø®É¡A®e©ö±N¯f·½¶Ç¬V¦Ü¨ä¥LªºÂå°|¤H­û¡C

 

¬°¤FÁ×§K¥H¤W©Ò»¡³o¨Ç¦bªí­±¤W¯gª¬¬Ý¦ü»´·L¡A©Î¬Æ¦Ü¨S¦³¯gª¬¡A¥H¤Î¨º¨Ç¨S¦³³QÀË´ú¥X¨Óªº¯f¨Ò¡A±N¯f¬r¦b¤£ª¾¤£Ä±¤¤¶Ç¼½¨ì§ó»·ªº¦a¤è¡A¬Y¨Ç°ê®aªº·í§½¤w¸g±Ä¥Î¤F¡u¤@ºô¥´ºÉ¡vªº³B²z¤è¦¡¡C

 

·s¥[©Y¬F©²§ïÅܤF¤@¶}©l©Ò­q¤Uªºªì¨B¹jÂ÷ªº¶EÂ_¨Ì¾Ú¡A¤£½×¬O§_¦³±µÄ²¹L»PSARS¦³Ãöªº¤H­û¡A¥u­n¥X²{¤F¦³¥i¯à©MSARS¦³Ãöªº¯gª¬¡A´X¥G©Ò¦³ªº¤H³£­n³Q¹jÂ÷¨ÃºÊ±±¡C³o¼Ë¤@¡uºô¡v¥´ºÉªº³B²z¤è¦¡¡A¥]¬A¤F©Ò¦³¥u¦³»´·Lµo¿N¡B¯ÝµÄX¥ú¤ù²§±`ªº¯f¤H¡A¦Ó¥u­n¬O¦³©I§l¹D¯gª¬¥X²{¦Ó¦³µo¿Nªº¯f¤H³£³Q°e¶i·s«Ø¥ßªº¡uµo¿N¹jÂ÷¯f©Ð¡v¡A¥t¥~¥u­n¬O¥X²{¤F©I§l¨ì¯gª¬©Î¬O¯ÝµÄX¥ú¤ù¦³²§±`¦ÓµLªk¥H¨ä¥L­ì¦]¸ÑÄÀªº¯f¨Ò¡A³£³Q¥]§t¦b³o­Ó¡u¤jºô¡v©³¤U¡C¦b¦p¦¹ÄY®æªº¤èªk­I«áªº°ò¥»­ì¦]§Y¦b©ó¡G¯f±w·P¬VSARSªº¥i¯à©Ê¦b«ùÄòºÊ±±¨ä©I§l¹D¯gª¬¡BÅé·Å¡B¥Õ¦å²y¼Æ¥Ø¡]¬°¤FÆ[¹î¬O§_¦³¥Õ¦å²y¼Æ´î¤Öªº±¡§Î¡^¤Î¯ÝµÄX¥ú48¤p®É¤§«á¡A·|§ó¥[©úÅã¡C

 

¦b·s¥[©Yªº¤@¶¡Âå°|¡A±Ä¨ú¤F¥H¤W©Ò­z¤§±¹¬I¤T­Ó§«ô¤§«á¡A­ì¥»¦b¹jÂ÷¯f©Ð¤¤ªº275­Ó¯f¨Ò¡]¨Ã¤£±Ä¥ÎWHO©Òµo¥¬¤§¶EÂ_¨Ì¾Ú¡^¤¤¦³72­Ó¯f¨Ò¡AÀH«á³Q¥æ¥Iµ¹SARS±MªùÂå°|¡A¨Ã¥B¨S¦³¤G«×·P¬Vªº±¡ªpµo¥Í

 

¹jÂ÷ÀˬÌ

 

¤£©¯¦a¡A¦b¯e¯f¦­´Á¿ëÃÑSARS¯f±wªºÀËÅç¡A¨Ã¤£¹w´Á¯à«Ü§Ö¼sªxªº§Q¥Î¡A©Ò¥HSARS¹jÂ÷Àˬ̵{§Çªº¦­´Á¤¶²ÐÀ³¥Ñ½Ã¥Í·í§½¦Ò¼{¡C¶V¦h¯f¨Òªº¼Wªø¡A«h¹jÂ÷©MÀˬ̵{§Ç¶V¨S®Ä¡A¦]¦¹¡A·í¬y¦æ¯f¶Ç¼½®É¡A¦b¬y¦æ¯f¹w¨¾¹Lµ{¤¤¥²¶·¤Î¦­¹ê¬IÄY¼Fªº±¹¬I¡]Lipsitch¡^¡C

 

¤T¤ë¤¤¡A·s¥[©Y¡B­»´ä¡B©M¥[®³¤jªº½Ã¥Í©x­û¡A¹ê¬IÀˬ̹jÂ÷±¹¬I¥H¨¾¤îSARSªº¶Ç¼½¡A¦b·s¥[©Y¡A©Ò¦³»P³o¨Ç­ÓÅ馳¤@¯Å±µÄ²ªÌ¬Ò¹ê¬I©~®a¹jÂ÷¡A¹H¤Ï³B»@ª÷¡A¦pªG¨S¦³°t¦X¡A¥L­Ìªº®a¤¤·|³Q¸Ë¸mÄá¼v¾÷¨ÃÀ¹¤W¹q¤l¤â¾R¡]Mukherjee¡^¡C

2003¦~4¤ë4¤é¡A¬ü°ê±NSARS¦C¤JÀ³¹jÂ÷ªº¶Ç¬V¯f¡A¤@¶µÁ`²Îªk®×´£¨Ñ¤FCDC¡]¬ü°ê¯e¯fºÞ¨î§½¡^ªk«ß®Ú¾Ú¡A¦b¥²­n®ÉCDC¯à¹ê¬I¹jÂ÷Àˬ̡A¥H§@¬°±±¨î¯e¯f¶Ç¼½ªº³¡¥÷±¹¬I¡C

 

¹jÂ÷Àˬ̨ëD­­¨î¦bÂå°|©Î­xÀ礤¡A¦pªG¯f±w¯f­«µ{«×¤£¨ìÀò­ã¶i¤J¡A³Ì¦n±N³oÃþ¯f±w°e¦^®a¤¤¡A¥H­t³d¥ôªº¤è¦¡­­¨î¯f±wªº¬¡°Êª½¨ì¥L­Ì¤wµL¯gª¬¡]Masur¡^¡C

SARS Co-V¯à¦bÀˬ̹jÂ÷ªÀ°Ï¤¤¶Ç¼½¡A¦Ü¤Ö¦³¤@¥÷³ø§iÅã¥ÜSARS Co-V¦b¹jÂ÷Àˬ̤¤¶Ç¼½¡]WHO WER 22/2003¡^¡C§âºÃ¦ü¡B¥i¯à©Mº¥Â¡ªº¯f¤H¨C4¦Ü6¤H©ñ¸m¦b¤@­Ó¹jÂ÷ªº¹j¶¡¡A¨Ã¤£¬O¾A·íÁ×§K¶Ç¬Vªº¤è¦¡¡C¤£­n»E¶°ºÃ¦ü¯f¨Ò¡A¥ô¦ó¯f¤H³Q¶EÂ_¦³SARS¡A¥i¯à¨ã¦³©Î¨S¦³SARS¯f¬r¡A¦ý¦pªG©M³Q¶Ç¬Vªº¯f±w³B¦b¤@°_«K·|©Ó¾á·P¬Vªº­·ÀI¡]Hom 2003b¡^¡C

 

´î¤Ö¦a°Ï®È¹C

 

¦b­»´ä³Ìªñ¤@¶µ¦³Ãö¶Ç¬V¯f¤ÀªR¤¤¡A¤@¶µ®È¹Cªº§¹¥þ¸T¥O¡A¥i¯à´î¤Ö76%ªº¶Ç¼½²v¡]Riley¡^¡A³o·t¥Ü·í¹ê½è¤WµLªk­°§C¥­§¡¦í°|ªvÀøªº®É¶¡®É¡A­­¨î¤j½d³ò¤H¤f²¾°Ê¡A¥i¯à¬O¤@­Ó¦³®ÄªººÞ¨î±¹¬I¡CÁ|¨Ò¦b¸ê·½³h½Cªº°ê®a¡A©Î¦pªG¤@¨Ç¹L«×¶Ç¼½ªº¨Æ¥ó¡Aºò±K±µÄòµo¥Í¡A«hÂå°|®e¶q·|¼È®É¶W¹L­t²ü¡]Riley¡^¡C

 

¥X°|«á¹jÂ÷

 

¦³¤@ÂIÃö©ó¥X°|«á¹jÂ÷´Á¶¡ªº¥i¾a¸ê°T¡A¦b·s¥[©Y¡A©Ò¦³¥Ñ¤§«e¦³SARS¯f¨ÒªºÂå°|¥X°|ªº¦í°|¯f¤H»Ý¹q¸ÜºÊµø21¤Ñ¡A©Ò¦³ªº¥i¯àSARS¦í°|¯f¤H©M³Q¿ï¬°ºÃ¦üSARS¦í°|¯f¤H¡A´_­ì¥X°|«á¶·©~®a¹jÂ÷14¤Ñ¡]MMWR 52; 405- 11¡^¡C

 

 

ÂåÅ@Àô¹Òªº·P¬V±±¨î

 

¤@¯ë©Ê±¹¬I

 

Âå°|¤u§@¤H­û¤´µM¯¸¦b¥þ²ySARS¬Ì±¡ªº³Ì«e½u¡C¥L­Ì³B©ó¥¼¨¾Å@ªº¼ÉÅS¥i¯à¤U¡A·P¬VSARSªº­·ÀI«D±`¦a°ª¡C¬°¤F«OÅ@ÂåÅ@¤H­û¡A¤]¬°¤F¨¾¤î¬Ì±¡ÂX´²¡AÄY®æªº·P¬V±±¨î±¹¬I©M¤½²³±Ð¨|¬O¥²¶·ªº¡C

 

¦bSARSÂå°|¡A©Ò¦³ÂåÅ@¤H­û³£¥²¶·¤@¤Ñ°O¿ý¨â¦¸Åé·Å¡C

 

¦b«DSARSÂå°|¡A¬°¤F´î¤Ö¯f±w±µÄ²©MÀ³¥I¥i¯à¨Ó¦ÛSARSÂå°|ªº¤u§@¶q¡A¶·¨ú®ø©Ò¦³¿ï¾Ü©Ê(«Dºò«æ)¤â³N©M«D¦í°|ªù¶E¡C¬°«OÅ@¦Û¨­¦w¥þ¡A±µÄ²¯f¤H®ÉÂåÅ@¤H­û¶·¬ïÀ¹N95(§t)¥H¤W¤f¸n¡B¤â®M©Mªø³T¡C¤u§@¬yµ{¶·¾¨¥i¯à´î¤Ö»P³æ¤@¯f±w±µÄ²ªº¤H­û¼Æ¥Ø©M±µÄ²®É¶¡¡C¥Ñ©ó³æ¤@ÂåÅ@¤H­û¶Ç¬V¾ã­Ó³¡ªùªº¼ç¦b­·ÀI¡AÂåÀø³æ¦ì¤º¦A¤À¦¨¤H­û¤¬¤£±µÄ²ªº¤p¶¤¡C¦³¨Ç³¡ªù³W©w¤@¤p¶¤¶·«Ý¦b®a¤¤¡A¥H½T«O¦b¥t¤@¤p¶¤¦]¼ÉÅS¦Ó¹jÂ÷®É¡A¤´¦³¤H¤O¥iºû«ùºò«æªº¤u§@¡C

 

¨ä¥L±¹¬I¥]¬A°±¤î¨ì°|±´¯f¡A°£¤F¤p¨à¬ì¡B²£¬ì©M¨ä¥L³¡¥÷¯f±w¡C³o¨Ç¯f±wªº³X«È¶·­­¬°¤@­Ó¤H¡A¦Ó¥BÀ¹¤W¤f¸n©M³q¹LÅé·ÅÀË´ú¡F¨ä¥L¶·¥Ñ¿ý¼v³Xµø¡C²{¥¿¶i¦æ·P¬V±±¨î¿ìªkªº½]®Ö¡C

 

¬°¤FÁ×§K±NSARS¤Þ¤JÂå°|¡A³Ì²×±N³]¥ß¾A·íªº©I§l¹D¹w¨¾±¹¬I¡A¥Hµû¦ô¥¼½T©w¶EÂ_ªº©I§l¹D¯gª¬¯f¤H¤Î¨ä®aÄÝ¡C

 

 

«OÅ@±¹¬I

 

­¸ªj¶Ç¬V¥i¯à¬OSARS¯f¬r¦bÂåÀø¾÷¨î¤¤¥D­nªº¶Ç¼½³~®|¡]Seto¡^¡A¦b¤@¶µ¬ã¨s¤¤¡A¤­®a­»´äÂå°|ªº241¦ì¥¼·P¬VªÌ¤Î13¥¼·P¬VªÌ¦³ÃÒ¾ÚÅã¥Ü´¿¼ÉÅS±µÄ²11¦ì¼Ð°O±wªÌ¡A¨ä¤¤69¦ì¥¼·P¬VªºÂåÀø¤u§@ªÌ¬O¦³¨Ï¥Î¤f¸n¡B¤â®M¡B¨¾Å@¦ç¨Ã±`¬~¤âªº¡AN95¤f¸nµ¹¤©¼ÉÅSªºªºÂåÀø¤u§@ªÌ³Ì¦nªº¨¾Å@¡A¦Ó¯È½è¤f¸n¨ÃµLªk¦³®Ä­°§C·P¬Vªº¦MÀI©Ê¡]Seto¡^¡C

 

ªí¤@·§¬A¤F­¸ªj¶Ç¬Vªº¹w¨¾±¹¬I¡C¼i¦æ±j¨î©Ê·P¬V±±¨î±¹¬I¡A¯à¦³®Ä¹w¨¾SARS¶i¤@¨Bªº¶Ç¼½¡]Hsu¡^¡C

 

ªí¤@¡G­¸ªj¶Ç¬Vªº¹w¨¾±¹¬I¡]¦ÛChan-Yeung¡A­»´ä¯S§O¦æ¬F°ÏSARSªºÃzµo¡G¯f¨Ò³ø§i¡^

¡D¯f¤H¤@¦ý¥X²{¯gª¬§YÀ³°tÀ¹N95¤f¸n¡A¨Ã¥ß§Y³B¸m©ó­tÀ£ªº¹jÂ÷³]³Æ¤¤¡C

¡DÂåÀø¤u§@ªÌ¦b·ÓÅU³o¨Ç¯f±w¤¤¡A¤]À³°tÀ¹¬Û¦Pªº¤f¸n¡A¥H¤ÎÀY®M¡BÅ@¥ØÃè¡B¹jÂ÷¦ç©M¤â®M¡C

¡D¨C¤é¤Î©w´Áªº®ø¬rÀ³¹ý©³¡A¥Î¦¸´â»Ä·»²G¡]1000 ppm¡^(§Y0.1%º}¥Õ¤ô)¥J²Ó²M¬~®ø¬r§É¡B§ß¤â¡B§ÉÀYÂd¡B¦aªO©M¦U¶µ³]¬I¡C

¡D¹ï©ó´¡ºÞ¯f¤H¡A±K³¬ªº©â®ð¨t²Î¬O¥²¶·ªº¡A¥HÁ×§KªÅ®ð¬ªº|¼W¥[¯e¯fªº¶Ç¼½¡C

 

§ó¸Ô²Óªº¸ê°T½Ð°Ñ·Ó¤U­zªºCDC¡]¬ü°ê¯e¯fºÞ¨î§½¡^«ü¾É¤è°w¡C

¥Ñ©óSARS¯f¬r¥i¯à¦bÀô¹Ò¤¤¦s¬¡¼Æ¤Ñ¡A¥]¬AÄY±K®ø¬r¤Î½Ã¥Íµ{§Çªº¹w¨¾±¹¬I¡AÀ³¯à´£¨Ñ°ª¤ô¥­ªº¨¾Å@¡C

 

¬~¤â

 

¥ô¦ó¸IIJÁy©Î²´¤§«e¡A¬~¤â¬O¥²¶·ªº¡C

 

¤â®M

 

¥[®³¤j½Ã¥Í¸p«ØÄ³¡A·í·ÓÅ@ºÃ¦ü¬OSARS¯f¤H®É°tÀ¹Âù¼h¤â®M¡A²æ¤U¤â®M«á¥²¶·¬~¤â¡C

 

­±¸n

 

N95¤f¸n¥H0.1-0.3·L¦Ì²É¤l´ú¸Õ¡Aªo½è¯à³q¹L¦Ó¹ï©ó·L²É·ÏÃú¡A«h¦³¦Ü¤Ö95%ªº¹LÂo®Ä²v¡A¥¦¬O¨¾¼éªº¡A¥i©ó¤â³N¤¤¨Ï¥Î©Î°tÀ¹¡C¡¨N¡¨ªí¥Ü¡¨Not resistant to oil¡]¤£¯à§Üªo½è¡^¡¨¦Ó¡¨95¡¨ªí¥Ü95%ªº¹LÂo®Ä²v¡C¤U­±´XÂI¬O¥²¶·¨c°O¤ß¤¤ªº¡]Health Canada¡^¡C

 

¨k©Ê¦X¨­ªº¬ïµÛ©M¨í°®²bÄGŽªº­±®e¡A¯à´£¨ÑÂåÀø¤u§@ªÌ³Ì¦nªº«OÅ@¡C

 

®Ú¾Ú¥Í²£»s³yªÌªº«ØÄ³¡A¤f¸nÀ³¸Ó´ú¸Õ¬O§_¦X¨­ºò±K¡A¥t¥~¡A¨C¦¸À¹¤W¤f¸n®É³£¥²¶·Àˬd¬O§_¦X¾A¡AÀˬd¤f¸n®É°tÀ¹ªÌ­n¨³³t¦³¤Oªº§l®ð¡A¨Ó½T©w¤f¸n¬O§_»PÁyºò±K§k¦X¡C

 

±Ð¾É¦p¦ó³Ì¨Î¨Ï¥ÎN95¤f¸n©Î¥H¤Wªº©I§l«OÅ@³]³Æ¡A°Ñ¾\¥Í²£»s³yªÌ´£¨Ñªº¶Ç³æ©Î¨Ì·Ó¦a¤è³W«h¡C

 

¨S¦³¥ô¦ó¥Xª©¸ê®ÆÅã¥Ü¤f¸n¹ï©ó°tÀ¹ªÌ¦³®Äªº®É¶¡¡A¥[®³¤j½Ã¥Í¸p«ØÄ³·í¤f¸nÅܼéÀã¡B¤zÂZ©I§l¡B¯}·l©Î©úÅãż¦Ã®É¡AÀ³´À´«¡C

 

¤f¸n¦b±µÄ²¼ÉÅS©ó¥i¯à¬OSARS¯f¨Ò¡A§YÀ³·í§@¤w¦Ã¬V¡A¨Ã¥á±ó¡C

 

¥á±ó¤f¸n¡B©Î¸IIJ¤f¸n«e¡A¥ý¬~¤â¡A¤p¤ßªº§â±a¤l²æ±¼¡C¥á±ó¡A©Î¸IIJ¤f¸n«á¡A¤]­n°O±o¬~¤â¡C

 

¦pªG­n¦A¨Ï¥Î¤f¸n¡G©ñ¸m¦b¦p¯È³U°®²b°®Àꪺ¦a¤è¡C¤£­n¥Îµ§©Î¼ÐÅÒª½±µ¼Ð¥Ü¦b¤f¸n¤W¡A©Ò¦³ªÌªº¦W¦rÀ³¼g¦b¯È³U¤W¥H¿ëÃѤf¸n¡A¸IIJ¤f¸n«e«áÀ³¬~¤â¡C

 

ªÀ°ÏÂå¥Í¦b±µÄ²¥ô¦ó¦³©I§l¹D¯gª¬ªº¯f¤H®É¡A«ØÄ³°tÀ¹N95¤f¸n¡]Chan-Yeumg¡^¡C

 

ÃB¥~«OÅ@

 

¤â³N´U¥i¥H´î¤Ö¤u§@¤H­û±µÄ²§t­¸ªjªºÀY¾v¡A¦Ó¦Ã¬V¤âªº¦MÀI¡C·sªº«aª¬¯f¬r¯S©Ê¥i¯à·|¸g±µÄ²ÂH½¤©Î²´·ú´²¼½¡A¦]¦¹¦b¼ÉÅS©óSARS¦MÀI¤¤ªº²Ä¤@½uÂåÀø¤u§@¤H­û¡A«ØÄ³¥i¨Ï¥Î¨¾¤ôªø³S¹jÂ÷¦ç¡BÅ@¥ØÃè¡B¥þ­±¸n¡]Kamming¡^¡C

 

²æ¦ç

 

²æ¦ç¬Ý°_¨Ó¤ñ®e©ö¡A¹ê»Ú¬O§xÃøªº¡A¤´¦³¨ü·P¬Vªº¦MÀI¡C¥²¶·¨Ì¤U¦C¦¸§Ç¡G¤â®M¥ý¡B¹jÂ÷¦ç¦¸¤§¡B¬~¤â¡B²æ­±¸n¡B¦A²æ¤f¸n¡B¦A¦¸¬~¤âµ¥¡F¶·¨Æ¥ý¤@¦A½m²ß¡C¤@¨ÇÂåÀø¤u§@ªÌ¥i¯à¦]¦¹¬V¤WSARS¡AÁöµM¥L­Ì¦³¨Ï¥Î©Ò¦³«ØÄ³ªº¹w¨¾±¹¬I¡C

 

 

¯S®í±¡ªp

 

¯fµ{¶i®i§Ö³t¨Ã¥B¦b²Ä¤G¶g¦³ÄY­««y¹Âªº¯f¤H¡A¶·µø¬°°ª¶Ç¬V©Ê¡CÀ³¾¨¶qÁ×§K·|²£¥Í¼Q¥XÃú®ð(aerosols)ªºÂåÀøµ{§Ç(¦p¤ôÃúªvÀø(nebulized medication)¡BBiPAP¡BHFOV)¡C¦p¶·´¡ºÞ¡A¤]À³´î¤ÖÂåÅ@¤H­û¤£¥²­nªº¼ÉÅS¡A¥]¬AºÉ¶q´î¤Ö¦b³õÂåÅ@¤H­û¼Æ¥Ø¡A»P¾A·í³Â¾K©ÎÂí©w¯f¤H¥H´î¤Ö«y¹Â¡C

 

©Ò¦³°ª¦MÀIªºÂåÀøµ{§Ç¶·¥Ñ¸gÅçÂ×´IªºÂåÅ@¤H­û°õ¦æ¡C

 

¥[Å@¯f©Ð

 

Li et al¤w³]¥ß¤@®M²µuªº¥[Å@¯f©Ð·P±±±¹¬I¡C(±NSARSÄY­«¯f±w¶°¤¤©ó¤@¶¡¥[Å@¯f©Ð¡F±N©Ò¦³ºÃ¦ü¯f¨ÒÂà°e¨ä¥LµLSARS¦¾¬Vªº¤¤¤ß¡F¥[Å@¯f©Ð­­¥Î©óSARS¯f¤H¡F«ü¥Ü¤H­û©M³X«È¶i¤J¯f©Ð«e¡A¦b«ü©w°Ï°ì¬ïÀ¹ªø³T¡B¤â®M¡B¾v®M¤Î¤f¸n¡F¥ô©R¡¨Äµ¹îÅ@¤h¡¨©âÀË¡A¥H½T©w¤f¸n¬O§_¥¿½TÀ¹¤W¡Fª½±µ·ÓÅU¯f¤H®ÉÀ³À¹¤WÅ@¥ØÃè©MÅ@­±ªOµ¥µ¥)

 

SARS¯f¤HÀ³Á×§K²£¥Í¤ôÃú®ð(nebulizer medication) ªºªvÀø¡C

 

SARS¯f±w´¡ºÞ

 

¦b¬Y¨Ç°ª¦MÀIªº±¡ªp¤U(¦p®ðºÞ´¡ºÞ¡B¤ä®ðºÞÃèÀˬd¡B©â·ð)¡A¥Ñ©ó¯S§O¤j¶qªº¯f¬r¼ÉÅS¡A¥i¯àµo¥ÍªÅ®ð¶Ç¼½·P¬V¡C

 

¬°´î¤Ö³Â¾KÂå®v¦b¬°SARS¥i¯à¯f¨Ò´¡ºÞªº­·ÀI¡A¥Ø«e³Ì¨Î±Ä¨ú±¹¬I¬O¥ÑToronto Western Hospital(Kamming et al.)ªºKamming, Gardam, Chung¤T¤H³]¥ß¡G

 

1.      ¥ý­pµe¦n¡C»Ý¤­¤ÀÄÁ¬ïÀ¹©Ò¦³¨¾Å@¹jÂ÷¸Ë³Æ¡C

2.      ¬ïÀ¹N95¤f¸n¡B©ß±ó¦¡¾c®M¡Bªø³T©M¤â®M¡CÀ¹¤Wªþ±a¦¡AirMateTM¨Ã±µ¤W©I§l¾¹ºÞ¤l©MTyvek©ÀY¸n¡C±µµÛ¬ï¤WÃB¥~ªºªø³T©M¤â®M¡C©Ò¦³¨ó§U¤H­û¶·¬ï¤W¬Û¦P¸Ë³Æ¡C­YµLªk¨ú±o°Ê¤O©I§l¾¹¡A´N§ïÀ¹¤WN95¤f¸n¡BÅ@¥ØÃè¡B©ß±ó¦¡¤â³N´U©M©ß±ó¦¡¥þÁyÅ@­±ªO¡C

3.      ¥Ñ¸gÅç³ÌÂ×´Iªº³Â¾KÂå®v¶i¦æ´¡ºÞ¡C

4.      Àˬd¼Ð·ÇºÊµø¨t²Î¡BÀR¯ß¾ÉºÞ¡B»ö¾¹¡BÃĪ«¡B³q®ð¾¹©M©â§l¾¹¡C

5.      °£«D¯S®í±¡ªp¡AÁ×§K¯f¤H²M¿ô®É¡AÅÖºû¤ºµøÃè´¡ºÞ¡C¼QÃú¦¡§½³¡³Â¾K·|Ãú¤Æ¶Ç¼½¯f¬r¡C

6.      ­pµe§Ö³t»¤¾É³Â¾K(rapid sequence induction-RSI)¡A¨Ã½T«O¦³¸gÅ窺§U²z¨ó§UÀôª¬¬IÀ£(cricoid pressure)¡C¦p¯f±wªºªÍªw-°Ê¯ß¦å®ñ¿@«×®t·¥°ª¦Ó¥BµLªk§Ô¨ü°±¤î©I§l¤T¤Q¬í¡A©ÎµLªk¨Ï¥Îsuccinylcholine¡A¥i¯à¶·­n½Õ¾ãRSI¡C¦p¨Ï¥Î¤â°Ê¦¡³q®ð¡AÀ³¨Ï¥Î¤p¶qªº¼é®ð¶q¡C

7.      ¥ýµ¹¤­¤ÀÄÁ100%¯Â®ñ¡A¨Ã¶i¦æRSI¡C¥HÁ×§K¶·¤â°Ê³q®ð©M±q©I§l¹DÃú¤Æ¯f¬r¡C¦b­±¸n©M©I§l¨t²Î¶¡©Î­±¸n©MLaerdal bag¶¡¡A½T¹ê¨Ï¥Î°ª®Ä²v¨¾¤ô¹LÂo¾¹¡C

8.      ´¡ºÞ¨Ã½T»{®ðºÞ¤ººÞ¦ì¸m¥¿½T¡C

9.      ¸Ë¸m¦Û°Ê³q®ð¨Ãí©w¯f¤H¡C©Ò¦³©I§l¸Ë³Æ¥Î¶ì½¦Âù¼h©ÔÁå³U«Ê¦n¡A¡A¨Ã°e©¹²b¤Æ©M®ø¬r¡C

10.  Â÷¶}­tÀ£°Ï«á¡A§U²z¥H®ø¬r¾¯(accelerated hydrogen peroxide³Ì¨Î)À¿«øTyvekÀY¸n¡C¶·¤p¤ß¦a¨ø°£¨¾Å@¸Ë³Æ¡AÁ×§K¦¾¬V¦Û¨­(self-contamination)¡C¥~¼h¤â®M¥Î¨Ó²æ¥~³T©M¾c®M¡C¥á±ó¥~¼h¤â®M¡A¥H¤º¼h¤â®M²æ®ø¬r¹LªºÀY¸n©M¤º³T¡A±µµÛ²¾°£¤º¼h¤â®M¡CÀY¸n¶·¥á±ó¡AAirMateºÞ¸ô¶·¶i¦æ¤Ú´µ¼w®ø¬r¡A±a¤l«h¥H®ø¬r¾¯À¿«ø¡CN95¤f¸n©MÅ@¥ØÃè¦bÂ÷¶}©Ð¶¡«á¡A¤~¥i²æ¤U¡C

11.  ²¾°£¨¾Å@¸Ë³Æ«á¡AÁ×§K¦b¬~¤â«e¸IIJÁy³¡©ÎÀY¾v¡C

 

³Â¾K

 

¦p¦P³B²z©I§l¹Dªº±M·~¤H­û¡A³Â¾KÂå®v¤]¸g±`¼ÉÅS©ó¯f¤Hªº©I§l¹D¤Àªcª«¡A¨Ã«Ü¥i¯à±q¯f±w·P¬VSARS(Kamming)¡C

 

¥ô¦óSARSºÃ¦ü¯f±w¡AÀ³µø¬°°ª¦MÀI¸s¡C¦Ó­t³dªº³Â¾KÂå®v¶·¬ïÀ¹N95¤f¸n¡BÅ@¥ØÃè¡BÅ@­±ªO¡BÂù¼hªø³T¡BÂù¼h¤â®M©M¾c®M¡C²¾°£©M©ß±ó³o¨Ç¸Ë³Æ¡A¦Ó¤£¦¾¬V¦Û¨­¬O·¥¬°­«­nªº¡C±j¯P«ØÄ³³Â¾KÂå®v©M§U²z¨Ï¥Î°Ê¤O©I§l¨t²Î¡A¬°SARSºÃ¦ü¯f¨Ò¶i¦æ°ª¦MÀI©Ê²£¥Í¤ôÃúªº©I§lªvÀø¨BÆJ(aerosol generating airway procedure) (Kamming)¡C

 

À˶ˤÀÃþ

 

¿ëÃѨìÂåÀø³]¬I©Î¶E©Ò¨D¶E¯f¤H¡A¬O§_¦³·P¬VSARS¬O¤£®e©öªº¡A³o»Ý­n§ïÅÜÂåÀøµû¦ôªº³B²z¤è¦¡¡C·sª©ªºÀ˶ˤÀÃþ¼È®É«ü¾É¤è°w«ØÄ³¡A©Ò¦³ªù¶E©Î«æ¶Eªº¯f¤HÀ³¸g¥ß§Y¿zÀË¡A¥]¬Aµo¿N¡B©I§l¹D¯gª¬¡B³Ìªñ®È¹C¥v»P¬O§_±K¤Á±µÄ²SARSºÃ¦ü¯f±w¡C

 

-            Ãö©ó«D¦í°|ºÃªº¯f±w¿zÀËSARSªº«ü¤Þ¡A½Ð°Ñ¦Ò¡GUpdated Interim Domestic Guidelines for Triage and Disposition of Patients Who May Have Severe Acute Respiratory Syndrome (SARS) : http://www.cdc.gov/ncidod/sars/triage_interim_guidance.htm

 

 

ºô¸ô¸ê·½

 

´£¨ÑºÃ¦üSARS¯f±wÂåÀø·ÓÅUªº·P¬V±±¨î¹Î¶¤¡A¥H¤Î¥ô¦ó¥i¯à±µÄ²ºÃ¦üSARS¯f±wªÌ¡AÀ³¸g±`ÂsÄý¬ü°ê°ê®a¯e¯fºÞ¨î§½(CDC)¡¨·P¬V±±¨î¤Î¼ÉÅS³B¸m¡¨­ì«h¡C(http://www.cdc.gov/nicdod/sras/ic.htm): (ªþµù¤G)

 

§ó·s°ê¤º¹ï©óºÃ¦üSARS¯f±wÂåÀø·ÓÅ@¡A¤ÎªÀ°Ï³]¸m·P¬V±±¨î¼È®É­ì«h¡A¥Ø«e¦b¶Ç¬V¾Ç®a¹ï©ó¯e¯fªº¶Ç¬V³~®|¦³§ó²`ªºÁA¸Ñ«e¡A¹w¨¾¬O³Ì¦nªº¤èªk(¸Ô¨£¤U¤èºô§})¡C

(http://www.cdc.gov/nicdod/sras/infectioncontrol.htm):

 

°ê¤º¨Ï¥Î¤f¸n¹w¨¾¶Ç¬VSARS¼È®É­ì«h¡C

(http://www.cdc.gov/nicdod/sras/respirators.htm): (ªþµù¤T)

 

¹ï©óºÃ¦üSARS¯f±w­¸ªjªº¹w¨¾¤Î·P¬V±±¨î¡C

(http://www.cdc.gov/nicdod/sras/aerosolinfectioncontrol.htm) (ªþµù¥|)

¹ï©ó·|²£¥Í¤ôÃú®ð­¸ªjªºªº¶EÀø(aerosolized medication)¦p:ÃĪ«¼Q¾¯(¨Òalbuterol) ¡A¶EÂ_©Ê»¤µo·ð¡A¤ä®ðºÞÃèÀˬd¡A©â·ð¡A¥H¤Î´¡ºÞµ¥¡A­n¯S§O¤p¤ß¡C

 

Ãö©ó¹êÅç«Ç¥Í¤Æ¦w¥þ³B²z¤Î¹B°eSARSÀËÅé¼È®É­ì«h

(http://www.cdc.gov/nicdod/sras/sarslabguide.htm): (ªþµù¤­)

 

¦P®É½Ð°Ñ·Ó¤å³¹¡¨¹ï©ó³B²zSARS±wªÌ¿òÅ骺·P¬V±±¨î­ì«h¡¨¥Ñ¥[®³¤j½Ã¥Í¤½§G¦b¥H¤Uºô§} http://SARSReference.com/link.php?id=17(ªþµù¤»)

 

¬ü°ê¯e¯fºÞ¨î§½(CDC): ¹ï©óºÃ¦üSARS¯f±wÂåÀø·ÓÅ@¤ÎªÀ°Ï³]¸m·P¬V±±¨î¼È®É­ì«h:

­×©w©ó¥Á°ê92¦~¤­¤ë¤@¤é¡A½Ð¸g±`¤WºôÂsÄý§ó·s:

http://www.cdc.gov/nicdod/sras/infectioncontrol.htm

¹ï©ó©Ò¦³¸òSARS¯f±wªº±µÄ²¡A±j¯P«ØÄ³®Ú¾Ú½Ã¥Í·Ç«h¡A¥]¬A¥ÎªÎ¨m©M¤ô¬~¤â¡A¦pªG¤â¨Ã¨S¦³©úÅãªg¦Ã¡A70-75%°sºë»s«~ªº¬~¤â²G¡A¥i¥H§@¬°´À¥N«~¡C

³sµ²¨ìwww.cdc.gov/handhygiene ¥HÀò±o§ó¦h¦³Ãö¤â³¡½Ã¥Í¡C

 

¹ï©ó¦í°|¯f¤Hªº³B¸m:

¦pªGºÃ¦üSARS¯f±w³Q¤¹³\°e¤JÂå°|¡A·P¬V±±¨î¤H­ûÀ³¥ß§Y´£°ªÄµÄ±¡A¹ï©ó¦í°|¯f±wªº·P¬V±±¨î¼Ð·Ç(http://www.cdc.gov/ncidod/hip/isolat/isolat.htm) À³¥]§t:

¼Ð·Ç¹w¨¾¨BÆJ:(¨Ò¦p:¤â³¡½Ã¥Í)¡A°£¤F¤@¯ë¤é±`ªº¼Ð·Ç¹w¨¾±¹¬I¡AÂåÀø·ÓÅU¤H­ûÀ³¸Ó¦b¹ï©ó±µÄ²©Ò¦³¯f±w®É¡A­n¨ØÀ¹Å@¥ØÃè¡C

±µÄ²¹w¨¾¨BÆJ:(¨Ò¦p:¦b±µÄ²¯f±w¤Î¥L­Ì©Ò³BªºÀô¹Ò¡AÀ³¨Ï¥Î¨¾Å@¦ç¤Î¤â®M)

ªÅ®ð¹w¨¾¨BÆJ:(¨Ò¦p:³]¸m¹jÂ÷­tÀ£¯f©Ð¡A¥H¤Î¦b¶i¤J¯f©Ð®É¨Ï¥Î©ß±ó¦¡ªºN-95¤f¸n) ¡C¦pªGªÅ®ð¹w¨¾µLªk¹ý©³¹ê¦æ¡A¯f±wÀ³³Q¦w¸m©ó¿W¥ß¯f©Ð¡A©Ò¦³¶i¤J¯f©Ðªº¤H­ûÀ³À¹N-95¤f¸n¡A¦pªG¥i¯à¡A¹ïN-95°µ¾A·í±K«Ê«×ªº´úÅç¡A¸Ô²Óªº´úÅç¸ê°T¥i³sµ²¨ìhttp://SARSReference.com/link.php?id=4 ¡A¦pªGµL¨¬°÷ªºN-95¤f¸n¥iµ¹©Ò¦³ªºÂåÀø¤H­û¡A«hÀ³À¹¤W¥~¬ì¤â³N¤f¸n¡A°£¤FªÅ®ð¹w¨¾¥~¡A¹ï©ó©Ò¦³ªººÃ¦üSARS¯f±w¡A³£À³±Ä¨ú¼Ð·Ç¹w¨¾¤Î±µÄ²¹w¨¾¡C

 

¹ï©óªù¶E¯f¤Hªº³B¸m:

·í¯f±w¦³«æ©Ê©I§l¹D·P¬V¦Ó´M¨DªvÀø¡AÀ³¥ý¸ß°Ý¦³µL©MSARS¯f±wªº±µÄ²¥v©Î¬O´¿¨ì¹LSARS  ¬Ì°Ï¡C¦pÃhºÃ¬OSARS¯f±w¡AÀ³´£¨Ñ¥~¬ì¤â³N©ÎN95¤f¸n¾B¦í¨ä¤f»ó¡A¦pªG¤f¸nµLªk¾A¥Î¡A«hÀ³­n¨D¨ä¦b«y¹Â¡A»¡¸Ü¡A¥´¼Q®÷®É¡A¥Î©ß±ó¦¡ªº¥¬®Æ¾B¦í¤f»ó¡AºÉ³t±N¯f±w±q¶E¶¡©M¨ä¥¦¤H¹jÂ÷¡A³Ì¦n¬O­tÀ£ªº³æ¤H¹jÂ÷¯f©Ð¡C

©Ò¦³¶i¦æÂåÀø·ÓÅUªº¤H­û¡A¦b·ÓÅUºÃ¦üSARS¯f±w®ÉÀ³À¹N-95¤f¸n¡A¦¹¥~ÂåÀø·ÓÅUªº¤H­ûÀ³¿í·Ó¼Ð·Ç¹w¨¾:(¨Ò¦p:¤â³¡½Ã¥Í)¡A±µÄ²¹w¨¾:(¨Ò¦p:¦b±µÄ²¯f±w¤Î¥L­Ì©Ò³BªºÀô¹Ò¡AÀ³¨Ï¥Î¨¾Å@¦ç¤Î¤â®M)¤Î±µÄ²©Ò¦³¯f±w®É¨ØÀ¹Å@¥ØÃè¡C

¦³Ãö©ó§ó¦hªº¸ê°V½Ð°Ñ·Ó¤ÀÃþ«ü¤Þ(http://www.cdc.gov/nicdod/sras/triage_interim_guidance.htm)¡C

 

¦í©Ò¤Î©~®aªº³B¸m:

ºÃ¦üSARS¯f±w¦b©M®a¤¤¨ä¥¦¤H±µÄ²®É¡A«ØÄ³À¹¤W¥~¬ì¤f¸n¡A¦pªG¯f±wµLªkÀ¹¤f¸n¡A·V­«°_¨£¡A¨ä¥¦ªº®a±Ú¦¨­ûÀ³¦bªñ¶ZÂ÷±µÄ²®É¡AÀ¹¤W¥~¬ì¤f¸n¡C¦Ó±µÄ²¯f±wªº®a®x¦¨­ûÀ³¨c°O¤â³¡½Ã¥Í¡A¥]¬A¥ÎªÎ¨m©M¤ô¬~¤â¡A¦pªG¤â¨Ã¨S¦³©úÅãªg¦Ã¡A70-75%°sºë»s«~ªº¬~¤â²G¥i¥H§@¬°´À¥N«~¡AÃö©ó§ó¦hªº¸ê°V½Ð°Ñ·Ó®a®x«ü¤Þ(http://www.cdc.gov/nicdod/sras/ic-closecontacts.htm) ¡C

 

ºÃ¦üÄY­«¶°©Ê©I§l¨ì¯g­Ô¸s(SARS)®×¨Ò©w¸q:

ÂåÀø·ÓÅ@¤H­û¹ï©ó±µÄ²¥ô¦ó©MºÃ¦üSARS¯f±wªº±µÄ²¡AÀ³¥Î¾A·íªº·P¬V±±¨î¤Î¹w¨¾±¹¬I¡A®×¨Ò©w¸q¬OÀH®ÉÅܤƪº¡A¯S§O¬O¦³Ãö©ó¨ä¥¦¦a²z°Ï³ø§i®È¹C¥v¡A°µ¬°¶Ç¬V³~«á¡F³Ì·s®×¨Ò©w¸q¥i³sµ²¨ìÄY­««æ©Ê©I§l¹D¯g­Ô¸s(SARS)®×¨Ò©w¸qºô­¶

(http://www.cdc.gov/nicdod/sras/casedefinition.htm)

 

¨ä¥¦¸ê°T

 

¤@­Ó²­nªº±Ô­z¤F¤½¦@½Ã¥Í¤z¹wªºPowerPoint ÀÉ¡A¦b³Ìªñ¥@¬É½Ã¥Í²Õ´(WHO)©óKuala Lumper·|ij¤Wµoªí¡C¡§ÄY­««æ©Ê©I§l¹D¯g­Ô¸s~­»´äªº¦^À³¡¨¥Ñ Yeoh EKµoªí: http://SARSReference.com/link.php?id=14

 

 

©~®a¶Ç¬V±±¨î

 

·í®a¸Ì¦¨­û¦³µo¿N©Î¨ä¥¦¦³ÃöSARSªº¯gª¬¥X²{®É¡A®a®x·ÓÅU¤u§@ªÌ¥²¶·©ê«ù°ª«×ªºÃhºÃ¡A¨Ã¥B±N¥L­Ì°e©¹Âå°|¡A¦Ó¤£¬OÅý¥L­Ì«Ý¦b®a¸Ì¡AÅý®a®x¨ä¥¦¦¨­û¼ÉÅS¦b¦MÀI¤§¤¤¡C

 

¹w¨¾¤G¦¸¶Ç¬V¡A»PSARS±wªÌ¦³ªñ¶ZÂ÷±µÄ²ªÌ¡A¥²¶·¹ïµo¿N¤Î©I§l¹D¯gª¬¦³©Òĵ±§¡C¦pªG¦³¯gª¬²£¥Í¡A¦³±µÄ²¹LSARS±wªÌªº¤H¡A­nÁ×§K»P¨ä¥L¤H±µÄ²¡A¥ß§Y´M¨DªºÂåÀø·ÓÅU¡A¨Ã¹ïSARS±wªÌ¹ê¦æ·P¬V±±¨î¹w¨¾±¹¬I¡CSARS¯f±wªº®a®x¦¨­û©M¦³»P¯f±w±K¤Á±µÄ²ªº¤H¡A³£À³¸Ó¥D°Ê±µ¨ü¦a¤èÂåÀø°|©ÒªººÊ±±¡C

 

¥i°Ñ¦Ò¯e¯f¶Ç¬VºÞ¨î§½¡]CDC¡^ªººô­¶¡G

n          SARS¶Ç¬V±±¨î»P¼ÉÅS³B²z

¡@¡@http://www.cdc.gov/ncidod/sars/ic.htm

 

n          SARSºÃ¦ü¯f±w©M¨ä®a¤H»P¨ä±K¤Á±µÄ²ªÌªº¶Ç¬V±±¨î¹w¨¾±¹¬I

¡@¡@http://www.cdc.gov/ncidod/sars/ic-closecontacts.htm

 

n          »PSARSºÃ¦ü¯f±w¦³¥i¯à±µÄ²¹Lªº¤Hªº³B²z¤è¦¡(ªþµù¤C)

¡@¡@http://www.cdc.gov/ncidod/sars/exposuremanagement.htm

 

n          ÂåÀø°|©Ò»PSARS¯f±w´¿¥h¹Lªº³õ©Òªº³B²z¤è¦¡(ªþµù¤K)

¡@¡@http://www.cdc.gov/ncidod/sars/exposureguidance.htm

 

¸ò½T©w¯f±w¦³±µÄ²ªº¤HÀ³¸Ó­n³Q¹jÂ÷¡Aª½¨ì¼ç¥ñ´Áµ²§ô¡C¸òSARS¯f±w±µÄ²«á¡AÀ³ª`­«¤â³¡½Ã¥Í¡A¥]¬A¥ÎªÎ¨m¤ô¬~¤â¡C

 

¤U­±¬O¤@¥÷¦³Ãö©ó

SARSºÃ¦ü¯f±w»P©M¯f±w¦³±K¤Á±µÄ²ªº®a¤H·P±±³B²z­ì«h¡]§ó·s¤é´Á¡G4/29¡^

 

SARS¯f±w·|¶Ç¬Vµ¹¸ò¥L­Ì¦³±K¤Á±µÄ²ªº®a¤H¡A©M·ÓÅU¥L­ÌªºÂåÅ@¤H­û¡A¤£½×¬O¦b¯gª¬µo¥Í«e©Îµo¥Í«á¡A¦ýSARS¯f±wªº¶Ç¬V´Á¤´¬O¥¼ª¾ªº(ĶªÌµù¡G¥Ø«eÂå¾Ç»{¬°¤j¦h¼ÆSARS¯f±w¦b¯gª¬¥X²{«á¡A¤~·|¶Ç¬V¡C)¡C¹ï©ó®a®x©ÎªÀ°Ï¤¤ªºSARSºÃ¦ü¯f±w¡A§Ú­Ìµ¹¤©¤U­±ªº·P¬V±±¨î¹w¨¾¬I¡A³o¨Ç«ØÄ³¬O®Ú¾Ú¬ü°êªº¸gÅç©Ò­×­qªº¡C

 

1.          SARSºÃ¦ü¯f±wÀ³­­¨î¥~¥X¬¡°Ê¡A¥]¬A¤u§@¡B¾Ç®Õ¡B¦«¨à©Ò¤Î¨ä¥L¤u§@³õ©Ò¡A¤@ª½¨ì¤Q¤Ñ«á¡A¥ô¦ó¥i¥HÃÒ©úSARS¯f±¡§ïµ½ªº±¡ªp¥X²{¡A¨Ò¦p°h¿N¡C¦b³o¦P®É¡AÀ³¹ê¦æ·P¬V±±¨î¹w¨¾±¹¬I¡A¨Ó­°§C¶Ç¬Vªº¥i¯à©Ê¡C

 

2.          SARSºÃ¦ü¯f±wªº©Ò¦³®a¤H¡AÀ³¸Ó¥J²Óªº¹ê¦æ¤â³¡½Ã¥Í²M¼ä¡]¨Ò¦p±`¬~¤â©Î¨Ï¥Î°sºëÀ¿¤â¡^¡A¯S§O¬O±µÄ²¯f±wªºÅé²G«á¡A¹³¬O©I§l¹D¤Àªcª«¡B§¿²G¡BÁT«K¡C°Ñ¦Ò¤U¦Cºô§}¦³§ó¦hªº¸ê°T¡Chttp://www.cdc.gov/handhygiene/

 

3.          ¥ô¦ó¸òSARSºÃ¦ü¯f±wªºÅé²G¦³ª½±µ±µÄ²¡A³£À³¸Ó¨Ï¥Î©ß±ó¦¡¤â®M¡CµM¦Ó¡A¤â®M¤£¯à¥N´À¬~¤â¡C¦b±µÄ²¯f¤HªºÅé²G¤§«á¡A¤â®MÀ³¥ß§Y²æ±¼¥á±ó¡A¨Ã¥B°¨¤W¬~¤â¡C¤â®M¤£¥i¥H¬~¹L¤§«á¦A­«½Æ¨Ï¥Î¡C

 

4.          ¨C¤@­ÓSARSºÃ¦ü¯f±w¦b«y¹Â©Î¥´¼Q®÷®É¡A³£À³¸Ó¥Î­±¯È¶ã¦í¼L¤Ú¡C¬°¤FÁ×§K¶Ç¬V¡ASARSºÃ¦ü¯f±w¦b¸ò¤@¯ë°·±d¤H±µÄ²®É¡AÀ³¸Ó°tÀ¹¥~¬ì¤â³N¥Î©ÎN95¤f¸n¡C¦pªGSARS¯f±wµLªk°tÀ¹¤f¸n¡A¥Lªº®a¤H¦b¸ò±wªÌ±µÄ²®É¡A´N¤@©w­n°tÀ¹¤f¸n¡C

 

5.          Á×§K¸òSARSºÃ¦ü¯f±w¯f±w¦@¥ÎÁç­Ñ¡BÀ\­Ñ¡B¸J¸_¡B¤ò¤y¤Î§ÉçE¡A§Y¨Ï³o¨ÇªF¦è²M¬~¤§«á¡A¥i¥H¦A¨Ï¥Î¡C½Ð°Ñ·Ó¨Ï¥Î»¡©ú¥¿½T¨Ï¥Î®ø¬r¾¯¡A²M²z³QSARSºÃ¦ü¯f±w¦¾¬VªºÀô¹Òªí­±¡F²M¼ä«á¡A¤â®MÀ³¥á±ó

 

6.          ³QSARSºÃ¦ü¯f±w¦¾¬Vªº®a®x¼o±óª«¡A¥]¬A­±¯È¤Î¤f¸n¡AÀ³¸Ó·í¥á±ó¡C

 

7.          SARSºÃ¦ü¯f±wªº®a®x¦¨­û©M¦³»P¯f±w±K¤Á±µÄ²ªº¤H¡A³£À³¸Ó¥D°Ê±µ¨ü¦a¤èÂåÀø°|©ÒªººÊ±±¡C

 

8.          SARSºÃ¦ü¯f±wªº®a®x¦¨­û©M¦³»P¯f±w±K¤Á±µÄ²ªÌ¡A¹ï©óµo¿N¤Î©I§l¹D¯gª¬À³¦³©Òĵı¡A¦pªG¯gª¬²£¥Í¤F¡A´NÀ³¸Ó´M¨DÂåÀø·ÓÅU¡C¦pªGÂåÀø°|©ÒµLªk½T©w¬O§_¬°SARS¡A´NÀ³¸Ó±Ä¨ú±¹¬I¡A¹w¨¾¶Ç¬Vµ¹°|¤º¨ä¥¦¤H¡]¦]¬°¸Ó¯f¤H»PSARSºÃ¦ü¯f±w¦³±K¤Á±µÄ²¡ASARSºÃ¦ü¯f±wªº®a®x¦¨­û¡A©M¦³»P¯f±w±K¤Á±µÄ²ªº¤H¡AÀ³¸Ó¿í±q»PSARS¯f¤H¬Û¦Pªº¹w¨¾±¹¬I¡^¡C

 

9.          ¦pªG¨S¦³µo¿N©Î©I§l¹D¯gª¬¡ASARSºÃ¦ü¯f±wªº®a®x¦¨­û©M¦³»P¯f±w±K¤Á±µÄ²ªÌ¡A¤£¥²­­¨î¥L­Ì¥X¥~¬¡°Ê¡C

 

¬ÛÃö³sµ²¡G

http://www.cdc.gov/ncidod/sars/closecontacts.htm

 

 

¸g¥Ñ°Êª«¶Ç¬Vªº¥i¯à©Ê

 

SARS¯f¬r¤w¸g¦b¤¤°ê«n¤è¥«³õ¤W³c½æªº¤TºØ°Êª«¡Ð¥Õ»ó¤ß¡B¸è¥H¤ÎÃ^õݨ­¤Wµo²{¡C¬°¤F¹w¨¾°_¨£¡A«ØÄ³©Ò¦³·|ª½±µ±µÄ²¨ì³o¨Ç°Êª«¡B©Î¬O¨äÅé²G¡B±Æªnª«ªº¤H­û¡A³£¥²¶·»{ª¾¨ì¦³SARS·P¬Vªº¦MÀI©Ê¡F¨ä¤¤¤S¥H¶R½æ¡B±O®_³o¨Ç°Êª«ªº¤H­û¡A±N¨ä³B²z²i½Õ¬°­¹ª«ªº¤H­û¡A¥H¤Î­¹¥Î³o¨Ç°Êª«ªº¤H³Ì¶·ª`·Nĵı¡C

 

 

¬Ì±¡¤jÃzµo¤§«á

 

·í¦h­Û¦h(Toronto)ªºSARS¬Ì±¡¤j¬y¦æ¤w¸g³Q»{¬°§i¤@¬q¸¨¡A¥¿·í·Ç³Æ»·Â÷SARS³±¼v¤§®É¡A¦b¥_¬ù§JÂå°|(North York General Hospital)¸Ì¡A¤@­Ó¥¼³Q¶EÂ_¥XªºSARS¯f¨Ò¡A«o¦A«×¤Þ°_¨ä¥L¯f¤H¡B±´¯f®aÄÝ¥H¤ÎÂåÅ@¤H­û¤§¶¡ªº¤G¦¸¤jÃzµo¡C

 

·P¬VºÞ¨î±¹¬I¸Ñ°£±o¤Ó§Ö¤F¡C¦b¤­¤ë¤W¡B¤¤¦¯ªº®É­Ô¡A¥Ñ©ó¦a°ÏªºSARS«ü´§¤¤¤ß«ØÄ³¡A¦UÂå°|«K¶}©l¸Ñ°£¤F¡A¹ï©Ò¦³¤£¨ã¦³©I§l¹D¯gª¬ªº«DSARS¯f¤H(«æ¶E»P¥[Å@¯f©Ð°£¥~)©Ò°µªºSARS¬ÛÃö¹w¨¾±¹¬I(¨Ò¦p¡G¹w¨¾©Ê¦aÀ¹¤WN95¤f¸n©Î¬O©I§l­±¸nµ¥µ¥)¡C¦AªÌ¡A¤@¯ë¤H­û¶i¥XÂå°|®É¡A¤]¤£¦A­n¨DÀ¹¤f¸n©Î©I§l­±¸n¡A¥ÎÀ\®É¤]¤£¦A­n¨D«O«ù¾A·í¶ZÂ÷¡C¦b¸Ó¶¡Ãzµo¤G¦¸¬y¦æªºÂå°|¸Ì¡A·P¬VºÞ¨î±¹¬Iªº©ñ¼e¬O±q¤­¤ë¤K¸¹¤~¶}©lªº¡F¥|¤p®É¤º¤@¦ì¯f±w¤´¦p¦P¤§«e¤@¼Ë¡A¥u¯à±µ¨ü¤@¦ì³X«Èªº±´µø¡AµM¦Ó³Q¤¹³\±´µøªº¯f±w¼Æ¥Ø¡A«o¸û³o¤§«e¼W¥[³\¦h¡C

 

¦]¦¹¡A¹ï©óÂåÅ@¤H­û¥H¤Î·P¬V±±¨î¤H­û¨Ó»¡¡A¹ïSARS«ùÄò«O«ù°ª«×ªºÄµ§Ù¤ß¬O«D±`­«­nªº¡A¤×¨ä¬O¦b³q³ø¯f¨Ò¼Æ¥Ø¶}©l´î¤Ö¤§®É§ó¬O¦p¦¹¡C­n¹w¨¾ÂåÀø·ÓÅ@ªº¹Lµ{¤¤¶Ç¼½SARSªº¸Ü¡A¥]¬A¤FÂåÅ@¤H­û¡B¯f¤H¡B³X«È¥H¤ÎªÀ°Ï¡A³o¨C¤@­ÓÀô¸`³£¤£¥i»´©¿¡C

 

 

µ²½×

 

¨´¤µSARS±Ð¤F§Ú­Ì³Ì­«­nªº½ÒÃD¤§¤@¡A´N¬O§Y¨Ï¬O¦b¨S¦³§¹µ½ªºÂåÀø³]³Æ©Î¤u¨ãªº¤U¡A¬F©²¾÷Ãö°ª¼h°w¹ï¬Ì±¡±±¨îªº¬Fµ¦¨M©w¡A¬O±±¨îSARS·P¬V¤£¥i©Î¯Ê¡CSARS¤w¸g¦b¤£¶¡Â_¦aÄY±K°õ¦æ¨¾ªv±¹¬I¤U¡A´X¥G­n³Q®Ú°£¤F¡C³o¨¾ªv±¹¬I´N¦p¦P¤w¸g¦³¦n´X¥@¬ö¾ú¥vªº¥j¦Ñ¶Ç¬V¯f±±¨îªk¡A¡Ð¹jÂ÷¡B°lÂܱµÄ²¥v¡BÀˬ̥H¤Î­­¨î®È¹C¡C¨ä¥Lªº¦¨¥\±¹¬I¡A¤S¥]¬A¦¨¥ßSARS±MªvÂå°|¡A¥HÁ×§KSARSÂX¤Î¨ä¥LÂå°|¡B¹B¥Î¤j²³¶Ç¼½´CÅé±Ð¨|¥Á²³¡A¨Ã¥B¹ªÀy¦³¯gª¬ªº¥Á²³¤Î¦­³q³ø´NÂå¡B¥H¤Î¦¨¥ßµo¿N¿zÀ˶EÀø¯¸¡A¨ÓµÎ½w¤wµo¥Í³\¦h·P¬V¯f¨Òªº«æ¶E³Bªº­t¾á¡C¦b¾÷³õ©Î¬O¨ä¥Lªº¥X¤J¹Ò¤fªº¿zÀË¡A¥H¤Î°w¹ï¦MÀI±Ú¸sªºµo¿NÀË´ú¡A³£±o¨ì¤F«Ü¦nªº®ÄªG¡C

 

³o¨Ç±¹¬I¡A³£¬O¬°¤F¯à¦­´Á°»´ú¦­´Á¹jÂ÷·s¼Wªº·P¬V¯f¨Ò¡A¦Ó³o´N¬O¥´Â_¶Ç¬V¸ô®|ªºÃöÁäÂI¡C­n§iª¾¤j²³­«­nªºÆ[©À¡A´N¬O¥´­ËSARS³Ì¦³¤OªZ¾¹¤£¬O§Oªº¡A´N¬O¨º¤ä·Å«×­p¦Ó¤w¡C

 

 

°Ñ¦Ò¸ê®Æ

 

1.      Booth CM, Matukas LM, Tomlinson GA, et al. Clinical features and short-term outcomes of 144 patients with SARS in the great Toronto area. JAMA 2003; 289:2801-9. Published online June 4. http://jama.ama-assn.org/cgi/content/full/289/21/2801

2.      CDC. Outbreak of Severe Acute Respiratory Syndrome ¡V Worldwide, 2003. MMWR 2003;52:226-228. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5211a5.htm

3.      CDC. Update: Outbreak of Severe Acute Respiratory Syndrome ¡V Worldwide, 2003. MMWR 2003;52:241-248. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5212a1.htm

4.      CDC. Severe Acute Respiratory Syndrome ¡V Singapore, 2003. MMWR 2003;52:405-11. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5218a1.htm

5.      CDC. Severe Acute Respiratory Syndrome ¡V Taiwan, 2003. MMWR 2003;52:461-66. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5220a1.htm

6.      CDC. Update: Outbreak of Severe Acute Respiratory Syndrome ¡V Toronto, Canada, 2003. MMWR 2003;52:547-50. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5223a4.htm

7.      CDC. Infection Control Precautions for Aerosol-Generating Procedures on Patients who have Suspected Severe Acute Respiratory Syndrome (SARS). March 20, 2003. http://www.cdc.gov/ncidod/sars/aerosolinfectioncontrol.htm (accessed May 3, 2003)

8.      Chan- Yeung M, Yu WC. Outbreak of severe acute respiratory syndrome in Hong Kong Special Administrative Region: case report, BMJ 2003; 326:850-2. http://bmj.com/cgi/content/full/326/7394/850

9.      Cho KO, Hoet AE, Loerch SC, Wittum TE, et al. Evaluation of concurrent shedding of bovine coronavirus via the respiratory tract and enteric route in feedlot cattle. Am J Vet Res 2001; 62; 1436-41. http://www.SARSRefernce.com/lit.php?id=11560274

10.  Donnelly CA, Ghani AC, Leung GM, et al. Epidemiological determinants of spread of causal agent of severe acute respiratory syndrome in Hong Kong. Lancet 2003; 361. Published online May 7, 2003.

11.  Drosten C, Gunther S, Presier W, et al. Identification of a Novel Coronavirus in Patients with Severe Acute Respiratory Syndrome. N Engl J Med 2003, 348:1967-76. Published online Apr 10, 2003. http://content.nejm.org/cgi/reprint/NEJMoa030747v2.pdf

12.  Dwosh HA, Hong H, Austgarden D, Herman S, Schabas R. Indentification and containment of an outbreak of SARS in a community hospital. CMAJ 2003; 168. Published online on Apr. 25, 2003. http://SARSReference.com/link.php?id=2

13.  Fisher DA, Chew M, Lim YT, Tambyah PA. Preventing local transmission of SARS: lessons from Singapore. MJA 2003; Published online May 19. http://www.mja.com.au/public/rop/fis10245_fm.pdf

14.  Government of Hong Kong Special Administrative Region, Department of Health. Outbreak of Severe Acute Respiratory Syndrome (SARS) at Amoy Gardens, Kowloon Bay, Hong Kong. Main Findings of the Investigation. http://www.info.gov.hk/info/ap/pdf/amoy_e.pdf (accessed April 30).

15.  Health Canada. Infection Control Guidance for Respirators (Masks) worn by Health Care Workers. Accessed July 3. http://SARSReference.com/link.php?id=13

16.  Health Canada. Infection Guidance for Handling of Human Remains of Severe Acute Respiratory Syndrome (SARS) Decedents. Accessed July 3. http://SARSReference.com/link.php?id=17

17.  Hon KL, Leung CW, Cheng WT, et al. Clinical presentations and outcome of severe acute respiratory in children, Lancet 2003, 361:1701-3. Published online April 29, 2003. http://image.thelancet.com/extras/03let4127web.pdf

18.  Hon K, Li AM, Cheng F, Leung TF, NG PC. Personal view of SARS: confusing definition, confusing diagnosis. Lancet 2003b;361: 1984-5.

19.  Hsu LY, Lee CC, Green JA, et al. Severe acute respiratory syndrome (SARS) in Singapore: clinical feature of index patient and initial contacts. Emerg Infect Dis 2003; 9: 713-7. http://www.cdc.gov/ncidod/EID/vol9no6/03-0264.htm

20.  Kamming D, Gardam M, Chung F. Anaesthesia and SARS. Br J Anaest 2003; 90: 715-8

21.  Masur H, Emanuel E, Lane HC. Severe acute respiratory syndrome ¡V proving care in the face of uncertainty. JAMA2003: 289: 2861-3. Published online May06, 2003.

22.  Mukherjee RK, Back MF, Lu JJ, Shakespeare TP, Wynne CJ. Hiding in the Bunker: Challenges for a radiation oncology department operating in the Severe Acute Respiratory Syndrome outbreak. Australasian Radiology 2003: 47: 143-5. http://SARSReference.com/lit.php?id=12780442

23.  Lee N, Hui D, Wu A, et al. A Major Outbreak of Severe Acute Respiratory Syndrome in Hong Kong. N Engl J Med 2003; 348: 1986-94. http://SARSReference.com/lit.php?id=12682352

24.  Li T, Buckley TA, Yap F, Sung J, Joynt GM. Severe Acute Respiratory Syndrome (SARS): infection control. Lancet 2003; 361. http://SARSReference.com/link.php?id=6

25.  Lipsitch M, Cohen T, Cooper B, et al. Transmission Dynamics and Control of Severe Acute Respiratory Syndrome. Science 2003; 300:1966-70. Published online May 23, 2003. http://www.sciencemag.org/cgi/content/full/300/5627/1966

26.  Peiris JSM, Lai ST, Poon LLM, Guan Y, Yam LYC, Lim W, et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet [early online release 2003 April 8]. Available: http://image.thelancet.com/extras/03art3477web.pdf (accessed April 24, 2003).

27.  Peiris JSM, Chu CM, Cheng VCC, et al. Prospective study of the clinical progression and viral load of SARS associated coronavirus pneumonia in a community outbreak. Lancet 2003. http://www.who.int/csr/sars/prospectivestudy/en/index.html

28.  Poutnen SM, Low DE, Henry B, Finkelstein S, et al. Identification of Severe Acute Respiratory Syndrome in Canada. N Engl J Med 2003, 348: 1995-2005. http://SARSReference.com/lit.php?id=12671061

29.  Rainer TH, Cameron PA, Smith D, et al. Evaluation of WHO criteria for identifying patients with severe acute respiratory syndrome out of hospital: prospective observational study. BMJ 2003; 326: 1354-8. http://bmj.com/cgi/content/full/326/7403/1354

30.  Riley S, Fraser C, Donnelly CA, et al. Transmission Dynamics of the Etiological Agent of SARS in Hong Kong: Impact of Public Health Interventions. Science 2003; 300: 1961-6. Published online May 23, 2003. http://www.sciencemag.org/cgi/content/full/300/5627/1961

31.  Seto WH, Tsang D, Yung R, et al. Effectiveness of precautions against droplets and contact in prevention of nosocomial transmission of severe acute respiratory syndrome (SARS). Lancet 2003; 361: 1519¡V20. http://sarsreference.com/link.php?id=1

32.  So L, Lau A, Yam L, Cheung T, Poon E, Yung R, Yuen K. Development of a standard treatment protocol for severe acute respiratory syndrome. Lancet 2003; 361:1615-6. http://sarsreference.com/link.php?id=12

33.  WHO. First data on stability and resistance of SARS coronavirus compiled by members of WHO laboratory network. May 4, 2003. http://sarsreference.com/link.php?id=5 (accessed May 4)

34.  WHO. Severe acute respiratory syndrome (SARS): Status of the outbreak and lessons for the immediate future. Geneva, 20 May 2003. http://www.who.int/csr/media/sars_wha.pdf

35.  WHO, WER 20/2003. SARS Outbreak in the Philippines.Weekly Epidemiological Record 2003; 78: 189-192. http://www.who.int/wer/pdf/2003/wer7820.pdf

36.  WHO, WER 22/2003. SARS Outbreak in the Philippines. Weekly Epidemiological Record 2003; 78: 189-192. http://www.who.int/wer/pdf/2003/wer7822.pdf

37.  WHO Update 50. WHO extends its SARS-related travel advice to Tianjin, Inner Mongolia and Taipei in China. http://www.who.int/entity/csr/sars/archive/2003_05_08/en

38.  WHO Update 64. Situation in Toronto, detection of SARS-like virus in wild animals. http://www.who.int/entity/csr/don/2003_05_23b/en

39.  WHO Update 70. Singapore removed from list of areas with local SARS transmission.http://www.who.int/entity/csr/don/2003_05_30a/en

40.  WHO Update 83. One hundred days into the outbreak. http://www.who.int/entity/csr/don/2003_06_18/en

41.  WHO Update 96. Update 96 - Taiwan, China: SARS transmission interrupted in last outbreak area. http://www.who.int/csr/don/2003_07_05/en/

42.  Yeoh E-k. National response to SARS: Peoples Republic of China. WHO Global Conference on Severe Acute Respiratory Syndrome (SARS). 17-18 June, 2003. Kuala Lumpur.

 

ĶªÌµù¡G°ò©ó³s±µºô¯¸¤W³\¦h­«­n°T®§­È±o°Ñ¦Ò¡AÁöµM­ì®Ñ¨S¦³°O¸ü¡A¤´±N¨äªþµù©ó¦¹¡A§Æ±æ¹ïŪªÌ¦³©Ò§U¯q¡C

 

ªþµù¤@¡G

°ê»Ú¥æ³q¾÷²î¹ï©óSARS¥i¯à¯f¨Òªº¹w¨¾»P³B²zªº«ØÄ³µ{§Ç

¦³Å³©ó«æ©Ê©I§l¹D¯g­Ô¸s(SARS)¦b¼Æ­Ó°ê®aªº¬y¦æ,¥@¬É½Ã¥Í²Õ´(WHO)¤w¸g¬°°ê»Ú¶¡®È¦æªº­¼«È¡A¥H¤Î¦U¦a¾÷³õªº½Ã¥Í¥DºÞ³æ¦ì­q©w¤F¤@®M¼Ð·Ç³B²zµ{§Ç¡A°w¹ïµÛºÃ¦ü«æ©Ê©I§l¹D¯g­Ô¸sªº­Ó®×¨ì¹F. ¯A¤Î¨ì¯èªÅ·~ªº¨C­Ó¤H©Î¬O¹ÎÅé©M¦³Ãö³æ¦ì,¥]§t¾÷²Õ­û,ÂåÀø¤H­û,¦a¶Ô¤H­û,©Ò¦³¤H¥H¤Î¾÷³õ½Ã¥Í¥DºÞ³æ¦ì¡AÀ³¸Ó¹ï³o¤@®Mµ{§Ç¦³µÛ²M·¡ªº²z¸Ñ¡C.

Ãö©ó«æ©Ê©I§l¹D¯g­Ô¸sªº¯gª¬¥H¤Î¬ÛÃö°T®§

©Ò¦³ªº°ê»Ú®È¦æªÌ¥]§t¾÷²Õ­û¡A¥H¤Î弦¨­¸¾÷ªº­¼«È¡A³£»Ý­nĵı¦Û¤v¥»¨­¦³¨S¦³¥H¤UÃö©ó«æ©Ê©I¨ì¯g­Ô¸sªº¯gª¬©Mªí²{

*Åé·Å¶W¹LÄá¤ó38«×ªº°ª¿N

¥H¤Î

*¤@­Ó¥H¤Wªº©I§l¹D¯gª¬¥]§t¦³«y¹Â,©I§lµu«P,©I§l§xÃø.

¡A¥H¤Î¤@­Ó¥H¤W¦p¤U©Ò¥Üªº¯gª¬

*©M³Q¶EÂ_¬°«æ©Ê©I§l¹D¯g­Ô¸sªº¤H¦³¹Lªñ¶ZÂ÷±µÄ²

*ªñ´Á(10¤Ñ¤º)¦³¥h¹L¦³µÛ·í¦aªº«æ©Ê©I§l¹D¯g­Ô¸s¶Ç¬V¤§°Ï°ì.

 

Â÷¹Ò«eªº¿zÀË

¦b¦³¹Ò¤º·P¬Vªº°Ï°ì, ©Ò¦³°ê»Ú¯è½uªº®È«È¥H¤Î¾÷²Õ¦¨­ûµn¾÷¤§«e¡A»Ý­n¶ñ¼g¤@¥÷²µuªº°Ý¨÷.¸Ì­±ªº°ÝÃD¬O¥]§t¦³¯gª¬ªº¦³µL,¬O§_»PºÃ¦ü·P¬VªÌ±µÄ²¥H¤Î³Ìªñªº®È¹C¥v¬O§_¦³¥]§t¦³¹Ò¤º·P¬Vªº°Ï°ì.

1) ¤@¦ýµo²{¦³»P«æ©Ê©I§l¹D¯g­Ô¸s¬ÛÃöªº¯gª¬,«h¸Ó¦ì¤H­û¥²¶·µ¥¨ì¨­Å骬ªp§¹¥þ±d´_¤~¥i¥HÄ~Äò®Èµ{.·í¦a½Ã¥Í¾÷Ãö­n°¨¤W§ä¥X±wªÌ¨Ã¥B§iª¾¥L.

2) ³ø§i­Y«ü¥X°·±dªº¤H¦b10¤Ñ¤§¤º¡A¦³¹Lªñ¶ZÂ÷±µÄ²«æ©Ê©I§l¹D¯g­Ô¸sªº¥i¯à­Ó®×,«h¸Ó¦ì¤H­û¤£±o¥X°ê.·í¦a½Ã¥Í¾÷Ãö­nÄU¾É¥Lª`·N¦Û¤v¦b¼ÉÅSªº10¤Ñ¤§¤º¡A¬O§_¦³«æ©Ê©I§l¹D¯g­Ô¸sªº¬ÛÃö¯gª¬¡A¨Ã«ùÄò»P½Ã¥Í¾÷Ãö«O«ùÁpµ¸.

3) ¹ï©ó¨S¦³¤W­z¯gª¬¤]¨S¦³±µÄ²¥vªº°·±d®È«È,À³´£¨ÑÃö©ó«æ©Ê©I§l¹D¯g­Ô¸sªº¬ÛÃö¿Ô¸ß¡A¨Ã¥B±Ð¾É¥L­Ì¦p¦ó¦b¦³¥ô¦ó¯gª¬®É¡A¯à°÷¥ß¨èªº±o¨ìÂåÀø¤Wªº¨ó§U.

¹ï©ó¾÷²Õ¤H­û»P­¼«È

¦b¥ý«eªºÂå¾ÇÀˬd¤§«á¡A¦pªG¥æ³q¤u¨ã¤WªºÂåÀø¤H­û»{¬°¦³ºÃ¦ü©Î¥i¯à¯f¨Ò¤§®É¡A¥²¶·¶i¦æ¥H¤Uµ{§Ç¡G

i) ³o¦ìºÃ¦ü¯f¨Ò¯f±w¥²¶·¹jÂ÷¦b¤@¿W¥ßªº¹jÂ÷²î¿µ¡B©Ð¶¡©Î°Ï°ì¡A¨Ã¥BºÉ¥i¯à¦a¨ÏªÅ½Õ©M±Æªn³]³Æ¡A»P¨ä¥L°Ï°ì¤À¶}¡C

ii) ¥]¬A©I§l¹D¶Ç¬V©Ê¤Î¤@¯ë©Ê¡A¨â¤è­±ªº¹w¨¾±¹¬I³£­n°µ¨ì¡C

iii) ³Q«ü©w·ÓÅU¯f±wªº¤H­û­n¬ïÀ¹¤f¸n¡B¤â®M¡BÅ@¥ØÃè¡A¨Ã¥B¦b±µÄ²¯f¤Hªº«e«á³£­n¬~¤â¡C

¾÷²î¤Wªº­t³d¤H­û¥²¶·¥ß§Y³qª¾¥Øªº¦a´ä¤f©Î¾÷³õªºÂåÀø¾÷Ãö¡A¸Ó¾÷²î¤W¦³ºÃ¦ü¯f¨Ò¡A¥H±oª¾¸Ó´ä¤f©Î¾÷³õ¬O§_¦³¨¬°÷±¹¬I¡A¨Ó¶i¦æ¯f±w·h¹B®Éªº¹jÂ÷¥H¤Î·ÓÅ@¡C¦pªG¸Ó´ä¤f©Î¾÷³õ¤£¨¬¥H´£¨Ñ¦¹ªA°È®É¡A¸Ó¾÷²î±N·|³Q­n¨D§ï©è¹F¦Ü¾Fªñªº´ä¤f©Î¾÷³õ¡A¥H¨ú±o¦¹ªA°È¡C

¹ï©ó²Å¦XºÃ¦ü©Î¥i¯à¯f¨Ò±ø¥óªº¯f±w¡A¥²¶·±N¯f±w¹jÂ÷¦b¿W¥ßªº©Ð¶¡°Ï°ì¤¤¡A°µ¦n§´·íªº¶Ç¬V¨¾½d±¹¬I¡Aª½¨ì°h¿N¡B©I§l¹D¯gª¬®ø¥¢©Î´î°hªº¤Q¤Ñ¤§«á¬°¤î¡C¤£¹L¡A¦pªG¯gª¬¨Ã¥¼¹F¨ì¯f¨Ò§P©w¼Ð·Ç¡A¦ý¬O«o¦³«ùÄò°ª¿N©Î«ùÄò¤£Â¡ªº©I§l¹D¯gª¬¤§®É¡A¤]­n¸T¤î¸Ó¯f±w¨ì¾÷²îªº¤½¦@°Ï°ì¡A©Î»P¨ä¥L¤H­û±µÄ²¡C·P¬V¹w¨¾±¹¬I¥]¬A¤F¹jÂ÷¡A¥H¤Î¶i¤@¨B¦a«ùÄòÆ[¹î¯gª¬ÅܤơC¨M©w¬O§_Åý¸Ó¯f±wÂ÷¶}¹jÂ÷©Ð¶¡©Î°Ï°ì¡A¥H¦^¨ì¤½¦@°Ï°ì¡A»Ý­n³z¹L³q°T»P¤½¦@½Ã¥Í¥DºÞ¾÷Ãö¡A¥H¤Î¥Øªº¾÷³õ´ä¤f¦@¦P¨ó½Õ¨M©w¡C©Ò¦³¦b¾÷²î¤ºªº±µÄ²¹ï¶H¡A¤]¥²¶·³Q©ú½T¦C¥X¨Ã¥B°O¿ý¡C

¦b¾÷²î¤W³B²z¦w¸m¯f¨Òªº¦P®É¡A¾÷²î¤º¤]¥²¶·¥H°ª«×²M¼ä®ø¬r¾÷²î¤ºÀô¹Ò¡A¥]¬A¤F¯f±w­ì¥»©Ò¦bªº²î¿µ°Ï°ì¡A¥H¤Î©Ò¦³¥i¯àªº±µÄ²¡C¦¹²M¼ä®ø¬rªºµ{§Ç¥i°Ñ¥[WHO©Î·í¦a¤½¦@½Ã¥Í¥DºÞ¾÷Ãö©Ò¤½¥¬¤§·Ç«h¡C

¡@

©è¹F°±¾a´ä¤f©Î¾÷³õ¤§®É

1.      ¦bÂåÀø³æ¦ìÀˬd¤F¸ÓºÃ¦ü©Î¥i¯à¯f¨Ò¡A¨Ã¥B½T»{¤ÎÀˬd¤F©Ò¦³¥i¯àªº±µÄ²¤H­û¤§«e¡A¤£¤¹³\¥ô¦ó¤HÂ÷¶}¸Ó¾÷²î¡C

2.      ¦pªG¸Ó´ä¤f©Î¾÷³õªºÂåÀø¤H­û¡A§P©w¸Ó¥Í¯fªº¾÷²Õ¤H­û©Î­¼«È¡A²Å¦XºÃ¦ü©Î¥i¯à¯f¨Ò±ø¥ó®É¡A»Ý¥Î©Ò¦³¥²¶·ªº¹w¨¾±¹¬I¤Î³]³Æ¡A¨Ó±N¸Ó¯f±w°e¦Ü¾FªñªºÂåÀø¾÷ºc¡C­Y¸Ó¯f±w«á¨Ó³Q§P©w¬°¥i¯à¯f¨Ò®É¡A©Ò¦³±µÄ²¹L¸Ó¯f±wªº¤H­û¡A³£¥²¶·¦Û§Ú¹jÂ÷¤Q¤Ñ¦Ó¥B¤£­ã®È¦æ¡C

3.      ¦b¸Ó¯f±wÂ÷¶}¾÷²î®É¡A¶·ºÉ§Ö¹jÂ÷¨Ã²M¼ä®ø¬r¾÷²î¤W¯f±w©Ò¦bªº°Ï°ì¡C

4.      ·í¦aªº½Ã¥Í¾÷Ãö¶·§iª¾¡A¤Î±Ð¨|©Ò¦³ªº­¼«È¤Î¾÷²Õ¤H­û¡AÃö©óSARSªº¯gª¬¤Î¶Ç¬Vµ¥¬ÛÃö¸ê°T¡C

5.      ¸Ó¾÷²î¥²¶·¦b·í¦a½Ã¥Í¾÷Ãö½T»{¡A¨S¦³¨ä¥Lªº¾÷²Õ¤H­û©Î­¼«È¦³SARS¯gª¬®É¡A¤~¯à³Q¤¹³\±Òµ{«e©¹¤U¤@­Ó°±¾a´ä¤f©Î¾÷³õ¡C

±µÄ²ªº³B²zµ{§Ç

©Ò¦³±µÄ²¨ìSARSºÃ¦ü©Î¥i¯à¯f¨Òªº¤H¡A³£¥²¶·³Q¸ÔºÉ§iª¾Ãö©óSARSªº¯gª¬¤Î¶Ç¬V¤è¦¡¡C³o¨Ç³Q±µÄ²¨ìªº¤H¡A¤]À³³Q­n¨D¦Û§Ú¹jÂ÷10¤Ñ¨Ã¥B³Q¥D°ÊºÊ·þ¡C­ì¥»¦b¾÷²î¤W·ÓÅ@­ì¯f±wªºÂåÀø¤H­û¡A¤]¥²¶·¨C¤Ñ´ú¶q¨Ã°O¿ýÅé·Å¡Cµn¾÷(²î)³B¤Î¤U¾÷(²î)³B¥²¶·°¨¤W¥[±j¹ï©óSARS±µÄ²¥i¯à¦h¥[ª`·N¡A¨Ã±Ä¨ú¶i¤@¨Bªº¹w¨¾±¹¬I¡C¦pªG©Ò¦³±µÄ²ªÌ¦b10¤Ñªº¦Û§Ú¹jÂ÷Æ[¹î´Á¤¤¡A¨Ã¥¼²£¥ÍSARSªº¯gª¬¡A¨º»ò´N¥i¥H¸Ñ°£¥H¤W©Ò­z¤§¬ÛÃöÄY±K¥[±j±¹¬I¡C

®ø¬rSARSºÃ¦ü©Î¥i¯à¯f¨Òªº©Ò¦b²î¿µ

½Ã¥Í²M¼ä¤H­û¥²¶·­n³Q¸ÔºÉ±Ð¾É¶Ç¬V±±¨îªº¸ê°T¡C·